Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sarepta Therapeutics, Inc. (SRPT)
USD18.14
-0.68 (-3.63%)
US NASDAQ Healthcare Biotechnology
Address
215 First Street 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
Douglas S. Ingram
Website
sarepta.com
IPO
1997-06-04
CIK 873303 ISIN US8036071004
Also trades on
London Stock Exchange · 0L35.L (USD)
NASDAQ Global Select · SRPT (USD)
Description
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD18.14
-0.68 (-3.63%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.21
Float Shares
92.95M
Free Float %
88.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.39% | -14.06% | -9.68% | +9.94% | +6.28% | -11.11% | -47.40% | -84.08% | -74.11% | +17.72% | -50.95% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (54 ratings, all time)
Buy
Price Targets & DCF
Current price
18.14
Low
14.00
-22.8%
Consensus
25.29
+39.4%
Median
25.00
+37.8%
High
35.00
+93.0%
Ratings Trend (MoM)
32% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 8 | 0 |
| Hold | 12 | -1 |
| Sell | 3 | 0 |
| Strong Sell | 2 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 5 |
27.00
+48.9%
|
| Last Year | 22 |
26.73
+47.4%
|
| All Time | 66 |
116.00
+539.6%
|
Quality scores
Altman Z-Score
0.20
Distress
Piotroski F-Score
8 / 9
Strong
MOAT Score
1 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+15.6% ★ Q1'26: -1.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-404.7% Q1'26: +162.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-28.9% Q1'26: -28.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-31.5% Q1'26: +49.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-55.8% Q1'26: +73.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-2.9% ★ Q1'26: +25.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.60× Q1'26: 0.70× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 12 EPS Ana. |
Dec 2027 16 Rev. Ana. 12 EPS Ana. |
Dec 2028 14 Rev. Ana. 12 EPS Ana. |
Dec 2029 9 Rev. Ana. 10 EPS Ana. |
Dec 2030 13 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.22M
est: 17.32M (-17.9%)
|
9.76M
est: 10.26M (-4.9%)
|
1.25M
est: 1.02M (+22.3%)
|
5.42M
est: 4.79M (+13.1%)
|
154.58M
est: 154.05M (+0.3%)
|
301.03M
est: 301.32M (-0.1%)
|
380.83M
est: 379.23M (+0.4%)
|
540.10M
est: 540.17M (0.0%)
|
701.89M
est: 695.42M (+0.9%)
|
933.01M
est: 924.70M (+0.9%)
|
1.24B
est: 1.50B (-17.4%)
|
1.90B
est: 1.85B (+2.9%)
|
2.20B
est: 1.86B (+18.2%)
|
1.79B
1.52B – 2.08B
-3.6% YoY
|
1.44B
1.06B – 1.85B
-19.6% YoY
|
1.40B
1.40B – 1.40B
-2.9% YoY
|
1.34B
1.06B – 1.62B
-4.5% YoY
|
1.31B
1.05B – 1.59B
-1.7% YoY
|
| EBITDA |
-88.42M
est: -86.58M (-2.1%)
|
-129.97M
est: -122.85M (-5.8%)
|
-214.78M
est: -178.37M (-20.4%)
|
-261.12M
est: -287.18M (+9.1%)
|
-34.76M
est: -64.50M (+46.1%)
|
-316.66M
est: -229.24M (-38.1%)
|
-658.71M
est: -502.15M (-31.2%)
|
-453.38M
est: -226.19M (-100.4%)
|
-317.41M
est: -340.92M (+6.9%)
|
-594.85M
est: -328.34M (-81.2%)
|
-453.69M
est: -476.43M (+4.8%)
|
316.89M
est: -585.15M (+154.2%)
|
-647.97M
est: -588.81M (-10.0%)
|
-567.73M
-657.04M – -481.61M
+3.6% YoY
|
-456.47M
-586.88M – -335.36M
+19.6% YoY
|
-443.01M
-443.67M – -442.34M
+2.9% YoY
|
-423.28M
-513.10M – -336.67M
+4.5% YoY
|
-416.01M
-504.28M – -330.88M
+1.7% YoY
|
| EBIT |
-90.28M
est: -93.55M (+3.5%)
|
-133.79M
est: -125.64M (-6.5%)
|
-218.67M
est: -182.71M (-19.7%)
|
-266.73M
est: -293.16M (+9.0%)
|
-42.83M
est: -72.58M (+41.0%)
|
-328.90M
est: -247.97M (-32.6%)
|
-683.21M
est: -548.73M (-24.5%)
|
-493.12M
est: -254.49M (-93.8%)
|
-355.42M
est: -486.41M (+26.9%)
|
-636.72M
est: -482.71M (-31.9%)
|
-498.09M
est: -529.05M (+5.9%)
|
279.17M
est: -649.78M (+143.0%)
|
-692.49M
est: -653.85M (-5.9%)
|
-630.44M
-729.61M – -534.81M
+3.6% YoY
|
-506.88M
-651.71M – -372.40M
+19.6% YoY
|
-491.94M
-492.68M – -491.20M
+2.9% YoY
|
-470.04M
-569.77M – -373.86M
+4.5% YoY
|
-461.96M
-559.98M – -367.43M
+1.7% YoY
|
| Net Income |
-111.99M
est: -87.74M (-27.6%)
|
-135.79M
est: -126.35M (-7.5%)
|
-220.03M
est: -182.59M (-20.5%)
|
-267.27M
est: -293.71M (+9.0%)
|
-50.69M
est: -82.87M (+38.8%)
|
-361.92M
est: -259.21M (-39.6%)
|
-715.08M
est: -555.47M (-28.7%)
|
-554.13M
est: -706.04M (+21.5%)
|
-418.78M
est: -435.96M (+3.9%)
|
-703.49M
est: -421.18M (-67.0%)
|
-535.98M
est: 47.30M (-1,233.2%)
|
235.24M
est: 271.90M (-13.5%)
|
-713.41M
est: -445.38M (-60.2%)
|
401.54M
233.63M – 548.72M
+190.2% YoY
|
84.37M
60.79M – 181.34M
-79.0% YoY
|
76.26M
-426.93M – 276.67M
-9.6% YoY
|
42.57M
31.25M – 54.32M
-44.2% YoY
|
41.36M
30.36M – 52.77M
-2.8% YoY
|
| SGA |
31.59M
est: 7.47M (+323.1%)
|
49.32M
est: 4.42M (+1,014.9%)
|
75.04M
est: 441.7K (+16,890.6%)
|
83.75M
est: 2.07M (+3,951.2%)
|
122.68M
est: 66.42M (+84.7%)
|
207.76M
est: 145.46M (+42.8%)
|
284.81M
est: 242.40M (+17.5%)
|
317.88M
est: 232.92M (+36.5%)
|
282.66M
est: 273.42M (+3.4%)
|
451.42M
est: 267.70M (+68.6%)
|
481.87M
est: 537.37M (-10.3%)
|
557.87M
est: 659.99M (-15.5%)
|
478.94M
est: 664.13M (-27.9%)
|
640.35M
543.22M – 741.08M
-3.6% YoY
|
514.85M
378.26M – 661.95M
-19.6% YoY
|
499.67M
498.92M – 500.42M
-2.9% YoY
|
477.43M
379.73M – 578.73M
-4.5% YoY
|
469.22M
373.21M – 568.78M
-1.7% YoY
|
| EPS |
-3.31
est: -2.49 (-32.9%)
|
-3.39
est: -3.27 (-3.7%)
|
-5.20
est: -4.85 (-7.2%)
|
-5.49
est: -5.03 (-9.0%)
|
-0.86
est: -0.77 (-11.9%)
|
-5.46
est: -4.41 (-23.8%)
|
-9.71
est: -7.97 (-21.8%)
|
-7.11
est: -6.55 (-8.6%)
|
-5.15
est: -5.11 (-0.8%)
|
-8.03
est: -8.06 (+0.4%)
|
-5.80
est: 0.50 (-1,268.9%)
|
2.47
est: 2.62 (-5.6%)
|
-7.13
est: -4.89 (-45.7%)
|
3.33
2.23 – 5.24
+168.1% YoY
|
1.00
0.58 – 1.73
-70.1% YoY
|
0.81
-4.07 – 2.64
-19.1% YoY
|
0.41
0.30 – 0.52
-49.7% YoY
|
0.39
0.29 – 0.50
-2.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-16 | HC Wainwright & Co. | Sell | Sell | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
93.14M
OE per share TTM
1.09
Owner's Yield
3.85%
Maintenance CapEx ratio
1.84%
Maint CapEx / Avg PPE
28.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
87
Total invested
97.99M
Insider transactions (90d)
0
Beneficial owners (>5%)
20
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group - 23-1945930 | 8.31M | 9.54% | — | 49.3K | 8.19M | 121.1K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 2 | EIN #00-0000000 | 7.25M | 8.30% | — | 7.25M | — | 7.25M | IA, HC | — | 2022-02-11 | ↗ |
| 3 | Sands Capital Management, LLC | 5.36M | 6.16% | 4.07M | — | 5.36M | — | IA | Delaware, United States | 2022-02-14 | ↗ |
| 4 | (1) BlackRock, Inc. | 5.29M | 6.10% | 5.00M | — | 5.29M | — | HC | Delaware | 2022-02-01 | ↗ |
| 5 | Capital Ventures International | 3.60M | 5.60% | 1.00M | 3.60M | 1.00M | 3.60M | CO | Cayman Islands | 2018-02-09 | ↗ |
| 6 | G1 Execution Services, LLC | 3.60M | 5.60% | 21.8K | 3.60M | 21.8K | 3.60M | BD, OO | Illinois | 2018-02-09 | ↗ |
| 7 | Susquehanna Advisors Group, Inc. | 3.60M | 5.60% | — | 3.60M | — | 3.60M | CO | Pennsylvania | 2018-02-09 | ↗ |
| 8 | Susquehanna Investment Group | 3.60M | 5.60% | 76.7K | 3.60M | 76.7K | 3.60M | BD, PN | Pennsylvania | 2018-02-09 | ↗ |
| 9 | Susquehanna Securities | 3.60M | 5.60% | 2.50M | 3.60M | 2.50M | 3.60M | BD, PN | Delaware | 2018-02-09 | ↗ |
| 10 | Jason H. Karp | 3.33M | 6.20% | — | 3.33M | — | 3.33M | IN | USA | 2016-10-28 | ↗ |
| 11 | Tourbillon Capital Partners LP | 3.33M | 6.20% | — | 3.33M | — | 3.33M | IA, PN | USA | 2016-10-28 | ↗ |
| 12 | 52-0556948 | 3.32M | 4.40% | 749.8K | — | 3.32M | — | IA | Maryland | 2020-02-14 | ↗ |
| 13 | Abigail P. Johnson | 2.96M | 3.39% | — | — | 2.96M | — | IN | Delaware | 2022-02-09 | ↗ |
| 14 | FMR LLC | 2.96M | 3.39% | 142.1K | — | 2.96M | — | HC | Delaware | 2022-02-09 | ↗ |
| 15 | Steven A. Cohen | 2.83M | 5.20% | — | 2.83M | — | — | IN | Delaware | 2017-02-23 | ↗ |
| 16 | Point72 Asset Management, L.P. | 2.82M | 5.20% | — | 2.82M | — | — | PN | Delaware | 2017-02-23 | ↗ |
| 17 | Point72 Capital Advisors, Inc. | 2.82M | 5.20% | — | 2.82M | — | — | CO | Delaware | 2017-02-23 | ↗ |
| 18 | Sun Life Financial Inc. | 2.19M | 7.44% | — | 2.36M | — | 2.36M | CO | Cayman Islands | 2016-05-06 | ↗ |
| 19 | Cubist Systematic Strategies, LLC | 5.9K | 4.00% | — | 5.9K | — | — | OO | Delaware | 2017-02-23 | ↗ |
| 20 | 95-1411037 | 13.00 | 5.10% | 4.74M | — | 4.74M | — | IA | Delaware | 2024-02-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
87
-299 vs prev Q
New positions
11
Closed positions
276
Increased
30
Reduced
36
Put/Call ratio
0.00
Calls held
1.5K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 14.28M +1.1M (+8.2%) | 307.38M +53.0M (+20.8%) | 14.25% +0.781 pp | 0.01% +0.001 pp | USD92.33 -76.7% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 11.81M +993.3K (+9.2%) | 254.17M +45.7M (+21.9%) | 11.78% +0.745 pp | 0.00% +0.001 pp | USD61.21 -64.8% | 54 qtrs — |
| 3 | AQR CAPITAL MANAGEMENT LLC | 7.80M +6.4M (+454.6%) | 167.78M +141.4M (+535.6%) | 7.78% +6.344 pp | 0.09% +0.071 pp | USD21.12 +1.9% | 5 qtrs — |
| 4 | STATE STREET CORP | 6.60M +1.3M (+24.4%) | 142.02M +39.8M (+38.9%) | 6.58% +1.171 pp | 0.00% +0.001 pp | USD77.99 -72.4% | 51 qtrs — |
| 5 | ERSTE ASSET MANAGEMENT GMBH | 2.73M +43.0K (+1.6%) | 58.73M +8.1M (+16.1%) | 2.72% -0.018 pp | 0.49% +0.004 pp | USD46.54 -53.8% | 29 qtrs — |
| 6 | TWO SIGMA INVESTMENTS, LP | 2.44M +303.7K (+14.2%) | 52.54M +11.3M (+27.5%) | 2.44% +0.254 pp | 0.07% +0.013 pp | USD30.20 -28.7% | 20 qtrs — |
| 7 | ABRDN PLC | 2.25M +268.8K (+13.6%) | 48.45M +10.2M (+26.8%) | 2.25% +0.223 pp | 0.08% +0.015 pp | USD44.38 -51.5% | 9 qtrs — |
| 8 | TWO SIGMA ADVISERS, LP | 2.07M +113.3K (+5.8%) | 44.58M +6.8M (+18.1%) | 2.07% +0.069 pp | 0.09% +0.011 pp | USD23.49 -8.4% | 17 qtrs — |
| 9 | UBS GROUP AG | 2.06M +68.2K (+3.4%) | 44.30M +5.9M (+15.5%) | 2.05% +0.023 pp | 0.01% +0.001 pp | USD44.21 -51.3% | 45 qtrs — |
| 10 | FIRST TRUST ADVISORS LP | 1.99M +52.8K (+2.7%) | 42.88M +5.5M (+14.7%) | 1.99% +0.009 pp | 0.03% +0.003 pp | USD38.54 -44.2% | 37 qtrs — |
| 11 | MORGAN STANLEY | 1.91M -35.7K (-1.8%) | 41.16M +3.6M (+9.6%) | 1.91% -0.080 pp | 0.00% +0.000 pp | USD82.45 -73.9% | 51 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.90M +183.2K (+10.6%) | 40.99M +7.8M (+23.6%) | 1.90% +0.144 pp | 0.00% +0.000 pp | USD82.33 -73.9% | 54 qtrs — |
| 13 | BANK OF AMERICA CORP /DE/ | 1.69M +891.5K (+111.0%) | 36.47M +21.0M (+135.7%) | 1.69% +0.871 pp | 0.00% +0.002 pp | USD51.06 -57.9% | 52 qtrs — |
| 14 | D. E. SHAW & CO., INC. | 1.54M -466.6K (-23.3%) | 33.15M -5.5M (-14.3%) | 1.54% -0.511 pp | 0.02% -0.004 pp | USD17.19 +25.2% | 27 qtrs — |
| 15 | LMR PARTNERS LLP | 1.45M +70.5K (+5.1%) | 31.26M +4.6M (+17.4%) | 1.45% +0.039 pp | 0.06% -0.059 pp | USD19.38 +11.0% | 2 qtrs — |
| 16 | FEDERATED HERMES, INC. | 1.31M +4.6K (+0.4%) | 28.26M +3.0M (+12.1%) | 1.31% -0.025 pp | 0.05% +0.003 pp | USD36.77 -41.5% | 25 qtrs — |
| 17 | RENAISSANCE TECHNOLOGIES LLC | 1.16M -1.5M (-56.2%) | 24.95M -26.1M (-51.1%) | 1.16% -1.547 pp | 0.04% -0.029 pp | USD18.76 +14.7% | 3 qtrs — |
| 18 | CITIGROUP INC | 1.15M +127.3K (+12.5%) | 24.67M +5.0M (+25.6%) | 1.14% +0.104 pp | 0.01% +0.002 pp | USD29.64 -27.4% | 54 qtrs — |
| 19 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 1.08M -662.3K (-38.0%) | 23.30M -10.3M (-30.7%) | 1.08% -0.700 pp | 0.06% -0.045 pp | USD31.14 -30.9% | 15 qtrs — |
| 20 | MILLENNIUM MANAGEMENT LLC | 1.00M +715.9K (+251.9%) | 21.52M +16.0M (+293.0%) | 1.00% +0.708 pp | 0.01% +0.007 pp | USD23.02 -6.5% | 53 qtrs — |
| 21 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 892.1K -474.6K (-34.7%) | 19.20M -7.1M (-27.1%) | 0.89% -0.505 pp | 0.01% -0.004 pp | USD54.35 -60.4% | 10 qtrs — |
| 22 | VOLEON CAPITAL MANAGEMENT LP | 880.0K +378.8K (+75.6%) | 18.94M +9.3M (+96.1%) | 0.88% +0.367 pp | 0.41% +0.171 pp | USD20.21 +6.5% | 3 qtrs — |
| 23 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 878.4K -430.3K (-32.9%) | 18.90M -6.3M (-25.0%) | 0.88% -0.459 pp | 0.07% -0.018 pp | USD31.59 -31.9% | 20 qtrs — |
| 24 | WHITEBOX ADVISORS LLC | 810.8K +— (+0.0%) | 17.45M +1.8M (+11.7%) | 0.81% -0.018 pp | 0.25% +0.006 pp | USD17.36 +24.0% | 3 qtrs — |
| 25 | 683 CAPITAL MANAGEMENT, LLC | 810.0K -180.0K (-18.2%) | 17.43M -1.6M (-8.6%) | 0.81% -0.202 pp | 0.76% -0.238 pp | USD30.30 -29.0% | 11 qtrs — |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 765.4K +156.2K (+25.6%) | 16.47M +4.7M (+40.3%) | 0.76% +0.142 pp | 0.00% +0.001 pp | USD72.24 -70.2% | 52 qtrs — |
| 27 | JPMORGAN CHASE & CO | 744.0K +74.6K (+11.1%) | 16.01M +3.1M (+24.1%) | 0.74% +0.059 pp | 0.00% +0.000 pp | USD108.80 -80.2% | 41 qtrs — |
| 28 | NORTHERN TRUST CORP | 733.4K +94.7K (+14.8%) | 15.78M +3.5M (+28.2%) | 0.73% +0.080 pp | 0.00% +0.000 pp | USD94.96 -77.3% | 51 qtrs — |
| 29 | BNP PARIBAS ARBITRAGE, SNC | 727.8K -1.1M (-59.1%) | 15.66M -18.7M (-54.4%) | 0.73% -1.092 pp | 0.01% -0.011 pp | USD19.40 +10.9% | 46 qtrs — |
| 30 | BANK OF NEW YORK MELLON CORP | 691.0K +100.8K (+17.1%) | 14.87M +3.5M (+30.7%) | 0.69% +0.087 pp | 0.00% +0.000 pp | USD89.55 -76.0% | 54 qtrs — |
| 31 | GOLDMAN SACHS GROUP INC | 563.5K +386.3K (+218.1%) | 12.13M +8.7M (+255.2%) | 0.56% +0.381 pp | 0.00% +0.001 pp | USD36.26 -40.7% | 54 qtrs — |
| 32 | JACOBS LEVY EQUITY MANAGEMENT, INC | 553.4K +291.0K (+110.9%) | 11.91M +6.9M (+135.6%) | 0.55% +0.284 pp | 0.05% +0.026 pp | USD19.49 +10.4% | 3 qtrs — |
| 33 | CITADEL ADVISORS LLC | 505.1K -105.5K (-17.3%) | 10.87M -896.5K (-7.6%) | 0.50% -0.119 pp | 0.00% 0.000 pp | USD38.54 -44.2% | 38 qtrs — |
| 34 | PRINCIPAL FINANCIAL GROUP INC | 497.3K +29.2K (+6.2%) | 10.70M +1.7M (+18.6%) | 0.50% +0.019 pp | 0.01% +0.001 pp | USD77.30 -72.2% | 38 qtrs — |
| 35 | C WORLDWIDE GROUP HOLDING A/S | 490.3K +— (+0.0%) | 10.55M +1.1M (+11.7%) | 0.49% -0.011 pp | 0.18% +0.039 pp | USD63.27 -66.0% | 37 qtrs — |
| 36 | CAPITAL FUND MANAGEMENT S.A. | 485.5K -294.6K (-37.8%) | 10.45M -4.6M (-30.5%) | 0.48% -0.312 pp | 0.03% -0.010 pp | USD43.43 -50.4% | 9 qtrs — |
| 37 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 479.2K +479.2K (+100.0%) | 10.31M +10.3M (+100.0%) | 0.48% +0.478 pp | 0.02% +0.017 pp | USD21.52 +0.0% | 1 qtrs NEW |
| 38 | IEQ CAPITAL, LLC | 475.0K +406.9K (+597.8%) | 10.22M +8.9M (+679.2%) | 0.47% +0.404 pp | 0.03% +0.027 pp | USD21.20 +1.5% | 2 qtrs — |
| 39 | DIMENSIONAL FUND ADVISORS LP | 458.1K -193.5K (-29.7%) | 9.86M -2.7M (-21.5%) | 0.46% -0.208 pp | 0.00% -0.001 pp | USD69.42 -69.0% | 32 qtrs — |
| 40 | CLEAR STREET GROUP INC. | 433.0K +433.0K (+100.0%) | 9.32M +9.3M (+100.0%) | 0.43% +0.432 pp | 0.03% +0.035 pp | USD21.52 +0.0% | 1 qtrs NEW |
| 41 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 427.6K -563.3K (-56.8%) | 9.20M -9.9M (-51.8%) | 0.43% -0.584 pp | 0.00% -0.001 pp | USD25.26 -14.8% | 51 qtrs — |
| 42 | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 400.0K +400.0K (+100.0%) | 8.61M +8.6M (+100.0%) | 0.40% +0.399 pp | 0.27% +0.274 pp | USD21.52 +0.0% | 1 qtrs NEW |
| 43 | INVESCO LTD. | 397.0K -435.6K (-52.3%) | 8.54M -7.5M (-46.8%) | 0.40% -0.454 pp | 0.00% -0.001 pp | USD49.44 -56.5% | 44 qtrs — |
| 44 | NORGES BANK | 370.7K +370.7K (+100.0%) | 7.98M +8.0M (+100.0%) | 0.37% +0.370 pp | 0.00% +0.001 pp | USD21.52 +0.0% | 1 qtrs NEW |
| 45 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 362.7K -18.5K (-4.9%) | 7.80M +459.4K (+6.3%) | 0.36% -0.027 pp | 0.03% -0.001 pp | USD19.27 +11.7% | 2 qtrs — |
| 46 | TANG CAPITAL MANAGEMENT LLC | 349.2K -250.8K (-41.8%) | 7.52M -4.0M (-35.0%) | 0.35% -0.264 pp | 0.37% -0.074 pp | USD17.75 +21.2% | 3 qtrs — |
| 47 | CANADA PENSION PLAN INVESTMENT BOARD | 346.8K +25.1K (+7.8%) | 7.46M +1.3M (+20.4%) | 0.35% +0.018 pp | 0.01% +0.001 pp | USD18.86 +14.1% | 3 qtrs — |
| 48 | RUSSELL INVESTMENTS GROUP, LTD. | 299.4K +131.1K (+77.9%) | 6.44M +3.2M (+98.7%) | 0.30% +0.127 pp | 0.01% +0.003 pp | USD41.46 -48.1% | 37 qtrs — |
| 49 | HRT FINANCIAL LP | 294.1K +112.3K (+61.7%) | 6.33M +2.8M (+80.6%) | 0.29% +0.108 pp | 0.02% +0.007 pp | USD24.89 -13.5% | 4 qtrs — |
| 50 | BRIDGEWATER ASSOCIATES, LP | 280.6K -71.7K (-20.4%) | 6.04M -750.5K (-11.1%) | 0.28% -0.080 pp | 0.02% -0.005 pp | USD19.27 +11.7% | 5 qtrs — |
| 51 | HUDSON BAY CAPITAL MANAGEMENT LP | 275.0K +75.0K (+37.5%) | 5.92M +2.1M (+53.6%) | 0.27% +0.070 pp | 0.02% +0.007 pp | USD55.10 -60.9% | 10 qtrs — |
| 52 | UBS ASSET MANAGEMENT AMERICAS INC | 266.5K +33.1K (+14.2%) | 5.74M +1.2M (+27.5%) | 0.27% +0.028 pp | 0.00% +0.000 pp | USD99.05 -78.3% | 30 qtrs — |
| 53 | LEGAL & GENERAL GROUP PLC | 264.5K -2.1K (-0.8%) | 5.69M +554.5K (+10.8%) | 0.26% -0.008 pp | 0.00% +0.000 pp | USD90.41 -76.2% | 46 qtrs — |
| 54 | MARINER, LLC | 257.1K +202.8K (+373.5%) | 5.53M +4.5M (+428.8%) | 0.26% +0.201 pp | 0.01% +0.005 pp | USD21.04 +2.3% | 11 qtrs — |
| 55 | AQUATIC CAPITAL MANAGEMENT LLC | 246.3K +57.9K (+30.7%) | 5.30M +1.7M (+46.0%) | 0.25% +0.054 pp | 0.15% +0.083 pp | USD33.43 -35.6% | 4 qtrs — |
| 56 | CWM, LLC | 240.5K +167.8K (+230.8%) | 5.18M +3.8M (+269.5%) | 0.24% +0.166 pp | 0.01% +0.010 pp | USD21.19 +1.6% | 17 qtrs — |
| 57 | SCHRODER INVESTMENT MANAGEMENT GROUP | 235.0K +235.0K (+100.0%) | 5.05M +5.1M (+100.0%) | 0.23% +0.235 pp | 0.00% +0.004 pp | USD21.52 +0.0% | 9 qtrs — |
| 58 | NATIONAL BANK OF CANADA /FI/ | 223.9K +223.6K (+93,185.0%) | 4.82M +4.8M (+104,095.1%) | 0.22% +0.223 pp | 0.00% +0.004 pp | USD21.56 -0.2% | 17 qtrs — |
| 59 | GOTHAM ASSET MANAGEMENT, LLC | 221.7K +221.7K (+100.0%) | 4.77M +4.8M (+100.0%) | 0.22% +0.221 pp | 0.02% +0.017 pp | USD21.52 +0.0% | 1 qtrs NEW |
| 60 | AMERIPRISE FINANCIAL INC | 217.5K +224.0 (+0.1%) | 4.68M +493.7K (+11.8%) | 0.22% -0.005 pp | 0.00% +0.000 pp | USD94.07 -77.1% | 53 qtrs — |
| 61 | CERITY PARTNERS LLC | 212.3K +174.2K (+456.8%) | 4.57M +3.8M (+521.9%) | 0.21% +0.173 pp | 0.01% +0.006 pp | USD21.12 +1.9% | 2 qtrs — |
| 62 | POINT72 ASSET MANAGEMENT, L.P. | 207.5K +207.5K (+100.0%) | 4.47M +4.5M (+100.0%) | 0.21% +0.207 pp | 0.01% +0.005 pp | USD21.52 +0.0% | 1 qtrs NEW |
| 63 | ROYAL BANK OF CANADA | 207.0K -31.5K (-13.2%) | 4.45M -141.0K (-3.1%) | 0.21% -0.037 pp | 0.00% +0.000 pp | USD113.60 -81.1% | 51 qtrs — |
| 64 | NUVEEN, LLC | 196.7K +25.1K (+14.6%) | 4.23M +925.9K (+28.0%) | 0.20% +0.021 pp | 0.00% +0.000 pp | USD58.43 -63.2% | 4 qtrs — |
| 65 | SWISS NATIONAL BANK | 196.0K +24.5K (+14.3%) | 4.22M +913.1K (+27.6%) | 0.20% +0.021 pp | 0.00% +0.001 pp | USD69.82 -69.2% | 51 qtrs — |
| 66 | RAFFERTY ASSET MANAGEMENT, LLC | 195.3K +20.1K (+11.5%) | 4.20M +827.1K (+24.5%) | 0.19% +0.016 pp | 0.01% +0.004 pp | USD74.15 -71.0% | 28 qtrs — |
| 67 | SG AMERICAS SECURITIES, LLC | 191.4K -308.3K (-61.7%) | 4.12M -5.5M (-57.2%) | 0.19% -0.319 pp | 0.01% -0.027 pp | USD20.12 +7.0% | 8 qtrs — |
| 68 | RHUMBLINE ADVISERS | 190.1K +11.7K (+6.6%) | 4.09M +653.0K (+19.0%) | 0.19% +0.008 pp | 0.00% +0.001 pp | USD121.55 -82.3% | 51 qtrs — |
| 69 | CAPTION MANAGEMENT, LLC | 184.7K -485.9K (-72.5%) | 3.97M -8.9M (-69.2%) | 0.18% -0.500 pp | 0.03% -0.074 pp | USD20.99 +2.5% | 28 qtrs — |
| 70 | TREXQUANT INVESTMENT LP | 178.3K +17.7K (+11.0%) | 3.84M +742.0K (+24.0%) | 0.18% +0.014 pp | 0.03% +0.002 pp | USD37.96 -43.3% | 4 qtrs — |
| 71 | JUMP FINANCIAL, LLC | 168.9K -132.1K (-43.9%) | 3.63M -2.2M (-37.3%) | 0.17% -0.139 pp | 0.04% -0.025 pp | USD17.72 +21.4% | 17 qtrs — |
| 72 | WELLS FARGO & COMPANY/MN | 167.7K -160.9K (-49.0%) | 3.61M -2.7M (-43.0%) | 0.17% -0.168 pp | 0.00% -0.001 pp | USD54.49 -60.5% | 54 qtrs — |
| 73 | BOXER CAPITAL MANAGEMENT, LLC | 150.0K -100.0K (-40.0%) | 3.23M -1.6M (-33.0%) | 0.15% -0.105 pp | 0.71% -0.829 pp | USD19.05 +13.0% | 3 qtrs — |
| 74 | ALGERT GLOBAL LLC | 150.0K -202.0K (-57.4%) | 3.23M -3.6M (-52.4%) | 0.15% -0.210 pp | 0.05% -0.063 pp | USD39.06 -44.9% | 18 qtrs — |
| 75 | BALYASNY ASSET MANAGEMENT L.P. | 150.0K -233.0K (-60.8%) | 3.23M -4.2M (-56.3%) | 0.15% -0.241 pp | 0.00% -0.005 pp | USD17.63 +22.1% | 3 qtrs — |
| 76 | MARSHALL WACE, LLP | 143.5K +38.4K (+36.5%) | 3.09M +1.1M (+52.5%) | 0.14% +0.036 pp | 0.00% +0.001 pp | USD19.87 +8.3% | 13 qtrs — |
| 77 | GROUP ONE TRADING, L.P. | 140.8K +18.4K (+15.1%) | 3.03M +671.9K (+28.5%) | 0.14% +0.016 pp | 0.01% +0.001 pp | USD51.93 -58.6% | 26 qtrs — |
| 78 | MIRADOR CAPITAL PARTNERS LP | 140.0K +140.0K (+100.0%) | 3.01M +3.0M (+100.0%) | 0.14% +0.140 pp | 0.41% +0.413 pp | USD21.52 +0.0% | 1 qtrs NEW |
| 79 | GENERALI INVESTMENTS CEE, INVESTICNI SPOLECNOST, A.S. | 136.5K +12.8K (+10.4%) | 2.94M +553.9K (+23.2%) | 0.14% +0.010 pp | 0.21% +0.026 pp | USD19.34 +11.3% | 5 qtrs — |
| 80 | WALLEYE CAPITAL LLC | 128.2K +66.3K (+107.1%) | 2.76M +1.6M (+131.3%) | 0.13% +0.065 pp | 0.01% +0.004 pp | USD19.80 +8.7% | 14 qtrs — |
| 81 | PEAK6 LLC | 124.9K +— (+0.0%) | 2.69M +281.0K (+11.7%) | 0.12% -0.003 pp | 0.01% +0.002 pp | USD40.44 -46.8% | 5 qtrs — |
| 82 | JANE STREET GROUP, LLC | 118.4K -44.1K (-27.1%) | 2.55M -583.4K (-18.6%) | 0.12% -0.048 pp | 0.00% 0.000 pp | USD43.31 -50.3% | 6 qtrs — |
| 83 | NEO IVY CAPITAL MANAGEMENT | 118.4K +118.4K (+100.0%) | 2.55M +2.5M (+100.0%) | 0.12% +0.118 pp | 0.40% +0.402 pp | USD21.52 +0.0% | 1 qtrs NEW |
| 84 | BARCLAYS PLC | 112.3K +62.0K (+123.3%) | 2.42M -3.9M (-61.5%) | 0.11% +0.061 pp | 0.00% -0.001 pp | USD19.54 +10.1% | 3 qtrs — |
| 85 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 106.8K +63.0K (+143.9%) | 2.41M +1.4M (+138.1%) | 0.11% +0.062 pp | 0.00% +0.002 pp | USD20.60 +4.5% | 10 qtrs — |
| 86 | EDGESTREAM PARTNERS, L.P. | 108.7K -62.1K (-36.3%) | 2.34M -951.5K (-28.9%) | 0.11% -0.066 pp | 0.07% -0.030 pp | USD20.56 +4.7% | 11 qtrs — |
| 87 | ALLIANCEBERNSTEIN L.P. | 108.4K +20.1K (+22.7%) | 2.33M +630.9K (+37.1%) | 0.11% +0.018 pp | 0.00% +0.000 pp | USD97.88 -78.0% | 53 qtrs — |
| 88 | QUANTINNO CAPITAL MANAGEMENT LP | 107.6K +46.9K (+77.3%) | 2.32M +1.1M (+98.0%) | 0.11% +0.045 pp | 0.00% +0.002 pp | USD19.90 +8.1% | 3 qtrs — |
| 89 | PDT PARTNERS, LLC | 105.5K -10.8K (-9.3%) | 2.27M +30.0K (+1.3%) | 0.11% -0.013 pp | 0.15% +0.006 pp | USD43.51 -50.5% | 9 qtrs — |
| 90 | WILEY BROS.-AINTREE CAPITAL, LLC | 112.4K +112.4K (+100.0%) | 2.23M +2.2M (+100.0%) | 0.11% +0.112 pp | 0.01% +0.012 pp | USD21.52 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 161 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Moonvest ETF MNVT | 4.98% | 2.58M | 0.75% |
| 2 | First Trust NYSE Arca Biotechnology UCITS ETF FBTU.L | 2.84% | 401.0K | 0.60% |
| 3 | Invesco Biotechnology & Genome ETF PBE | 2.77% | 7.93M | 0.58% |
| 4 | First Trust NYSE Arca Biotechnology Index Fund FBT | 2.40% | 67.58M | 0.55% |
| 5 | Global X - Genomics & Biotechnology ETF GNOM | 1.67% | 1.45M | 0.50% |
| 6 | Global X - Genomics & Biotechnology UCITS ETF GNOM.L | 1.67% | 873.9K | 0.50% |
| 7 | Virtus Biotech ETF BBP | 1.60% | 1.57M | 0.34% |
| 8 | Harbor Human Capital Factor US Small Cap ETF HAPS | 1.03% | 1.76M | 0.61% |
| 9 | ALPS Medical Breakthroughs ETF SBIO | 1.02% | 2.17M | 0.50% |
| 10 | Invesco S&P SmallCap Health Care ETF PSCH | 0.87% | 1.43M | 0.29% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.36
Bearish
Ratio by volume
0.85
Neutral
Buys
9
Sells
25
Shares acquired
59.0K
Shares disposed
69.6K
Cash buys
—
Cash sales
1.00
Net activity
-10,611
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | Mayo Stephen | Director | S-Sale | D | Common Stock | 7,239 | 17.02 | 123.2K | 1,765 | D | ↗ |
| 2026-03-11 | Wong Ryan Ho-Yan | Officer | F-InKind | D | Common Stock | 256 | 17.03 | 4.4K | 135,064 | D | ↗ |
| 2026-03-11 | Rothfuss Cristin | Officer | F-InKind | D | Common Stock | 974 | 17.03 | 16.6K | 137,544 | D | ↗ |
| 2026-03-11 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 948 | 17.03 | 16.1K | 225,323 | D | ↗ |
| 2026-03-11 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 1,097 | 17.03 | 18.7K | 201,983 | D | ↗ |
| 2026-03-10 | Wong Ryan Ho-Yan | Officer | — | — | Stock Option (Right to buy) | 1,208 | 99.69 | 120.4K | 0 | D | ↗ |
| 2026-03-09 | Wong Ryan Ho-Yan | Officer | F-InKind | D | Common Stock | 113 | 16.95 | 1.9K | 135,320 | D | ↗ |
| 2026-03-09 | Rothfuss Cristin | Officer | F-InKind | D | Common Stock | 484 | 16.95 | 8.2K | 138,864 | D | ↗ |
| 2026-03-09 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 504 | 16.95 | 8.5K | 227,166 | D | ↗ |
| 2026-03-09 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 583 | 16.95 | 9.9K | 203,080 | D | ↗ |
| 2026-03-02 | Wong Ryan Ho-Yan | Officer | F-InKind | D | Common Stock | 450 | 16.20 | 7.3K | 135,595 | D | ↗ |
| 2026-03-02 | Rothfuss Cristin | Officer | F-InKind | D | Common Stock | 408 | 16.20 | 6.6K | 139,348 | D | ↗ |
| 2026-03-02 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 3,718 | 16.20 | 60.2K | 228,437 | D | ↗ |
| 2026-03-02 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 3,301 | 16.20 | 53.5K | 205,574 | D | ↗ |
| 2026-03-01 | Rodino-Klapac Louise | Officer | M-Exempt | A | Common Stock | 8,125 | 0.00 | — | 232,155 | D | ↗ |
| 2026-03-01 | Estepan Ian Michael | Officer | M-Exempt | A | Common Stock | 8,125 | 0.00 | — | 208,875 | D | ↗ |
| 2026-02-26 | Estepan Ian Michael | Officer | M-Exempt | A | Common Stock | 5,381 | 13.71 | 73.8K | 200,750 | D | ↗ |
| 2026-02-25 | Rodino-Klapac Louise | Officer | A-Award | A | Performance Stock Units | 1,875 | 0.00 | — | 8,125 | D | ↗ |
| 2026-02-25 | Estepan Ian Michael | Officer | A-Award | A | Performance Stock Units | 1,875 | 0.00 | — | 8,125 | D | ↗ |
| 2026-01-29 | Nicaise Claude | Director | F-InKind | D | Common Stock | 6,780 | 21.23 | 143.9K | 31,532 | D | ↗ |
| 2026-01-27 | BEHRENS M KATHLEEN | Director | M-Exempt | A | Common Stock | 10,500 | 13.71 | 144.0K | 203,976 | D | ↗ |
| 2025-12-18 | Chambers Michael Andrew | Director | A-Award | A | Convertible Senior Notes | 0 | 60.00 | — | 0 | I | ↗ |
| 2025-12-16 | Estepan Ian Michael | Officer | S-Sale | D | Common Stock | 13,187 | 22.31 | 294.2K | 193,300 | D | ↗ |
| 2025-12-07 | INGRAM DOUGLAS S | Director / Officer | A-Award | A | Common Stock | 269,542 | 0.00 | — | 929,391 | D | ↗ |
| 2025-12-01 | Wong Ryan Ho-Yan | Officer | F-InKind | D | Common Stock | 80 | 20.96 | 1.7K | 136,123 | D | ↗ |
| 2025-11-28 | Rothfuss Cristin | Officer | F-InKind | D | Common Stock | 229 | 21.12 | 4.8K | 139,756 | D | ↗ |
| 2025-11-17 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 4,582 | 18.42 | 84.4K | 224,030 | D | ↗ |
| 2025-09-03 | Wong Ryan Ho-Yan | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 136,203 | D | ↗ |
| 2025-09-03 | Rothfuss Cristin | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 139,985 | D | ↗ |
| 2025-09-03 | Rodino-Klapac Louise | Officer | A-Award | A | Common Stock | 93,875 | 0.00 | — | 178,612 | D | ↗ |
| 2025-09-03 | Estepan Ian Michael | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 206,487 | D | ↗ |
| 2025-08-05 | Rodino-Klapac Louise | Officer | A-Award | A | Performance Stock Units | 6,250 | 0.00 | — | 6,250 | D | ↗ |
| 2025-08-05 | Estepan Ian Michael | Officer | A-Award | A | Performance Stock Units | 6,250 | 0.00 | — | 6,250 | D | ↗ |
| 2025-08-05 | Arif Bilal | Officer | A-Award | A | Performance Stock Units | 6,250 | 0.00 | — | 6,250 | D | ↗ |
| 2025-07-31 | Wong Ryan Ho-Yan | Officer | F-InKind | D | Common Stock | 327 | 16.42 | 5.4K | 17,328 | D | ↗ |
| 2025-07-16 | Wong Ryan Ho-Yan | Officer | — | — | Common Stock | 0 | 0.00 | — | 17,655 | D | ↗ |
| 2025-05-16 | Barry Richard | Director | M-Exempt | A | Common Stock | 12,350 | 32.63 | 403.0K | 2,966,667 | D | ↗ |
| 2025-05-13 | Barry Richard | Director | M-Exempt | D | Stock Option (right to buy) | 9,746 | 25.18 | 245.4K | 0 | D | ↗ |
| 2025-03-12 | Nicaise Claude | Director | M-Exempt | A | Common Stock | 9,746 | 25.18 | 245.4K | 30,303 | D | ↗ |
| 2025-03-10 | Wigzell Hans Lennart Rudolf | Director | A-Award | A | Common Stock | 2,383 | 0.00 | — | 25,223 | D | ↗ |
| 2025-03-10 | Rothfuss Cristin | Officer | F-InKind | D | Common Stock | 491 | 100.13 | 49.2K | 12,834 | D | ↗ |
| 2025-03-10 | Rodino-Klapac Louise | Officer | A-Award | A | Common Stock | 8,276 | 0.00 | — | 84,631 | D | ↗ |
| 2025-03-10 | Nicaise Claude | Director | A-Award | A | Stock Options (right to buy) | 4,792 | 99.69 | 477.7K | 20,557 | D | ↗ |
| 2025-03-10 | Murray Dallan | Officer | A-Award | A | Common Stock | 8,276 | 0.00 | — | 38,202 | D | ↗ |
| 2025-03-10 | Mayo Stephen | Director | A-Award | A | Common Stock | 2,383 | 0.00 | — | 9,004 | D | ↗ |
| 2025-03-10 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 1,051 | 100.13 | 105.2K | 57,226 | D | ↗ |
| 2025-03-10 | Connelly Deirdre P | Director | A-Award | A | Stock Options (right to buy) | 4,792 | 99.69 | 477.7K | 4,792 | D | ↗ |
| 2025-03-10 | Chambers Michael Andrew | Director | A-Award | A | Stock Options (right to buy) | 4,792 | 99.69 | 477.7K | 4,792 | D | ↗ |
| 2025-03-10 | Boor Kathryn Jean | Director | A-Award | A | Common Stock | 2,383 | 0.00 | — | 8,263 | D | ↗ |
| 2025-03-10 | Barry Richard | Director | A-Award | A | Stock Options (right to buy) | 4,792 | 99.69 | 477.7K | 4,792 | D | ↗ |
| 2025-03-10 | BEHRENS M KATHLEEN | Director | A-Award | A | Stock Option (right to buy) | 4,792 | 99.69 | 477.7K | 4,792 | D | ↗ |
| 2025-03-10 | Arif Bilal | Officer | A-Award | A | Common Stock | 8,276 | 0.00 | — | 32,500 | D | ↗ |
| 2025-03-07 | Rothfuss Cristin | Officer | F-InKind | D | Common Stock | 347 | 103.70 | 36.0K | 11,847 | D | ↗ |
| 2025-03-07 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 514 | 103.70 | 53.3K | 82,308 | D | ↗ |
| 2025-03-07 | Murray Dallan | Officer | F-InKind | D | Common Stock | 549 | 103.70 | 56.9K | 36,772 | D | ↗ |
| 2025-03-07 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 9,094 | 103.70 | 943.0K | 52,777 | D | ↗ |
| 2025-03-07 | Arif Bilal | Officer | F-InKind | D | Common Stock | 508 | 103.70 | 52.7K | 33,274 | D | ↗ |
| 2025-03-06 | Rodino-Klapac Louise | Officer | M-Exempt | D | Performance Stock Units | 17,500 | 0.00 | — | 0 | D | ↗ |
| 2025-03-06 | Murray Dallan | Officer | M-Exempt | A | Common Stock | 17,500 | 0.00 | — | 37,321 | D | ↗ |
| 2025-03-06 | Estepan Ian Michael | Officer | M-Exempt | D | Performance Stock Units | 17,500 | 0.00 | — | 0 | D | ↗ |
| 2025-03-06 | Arif Bilal | Officer | M-Exempt | A | Common Stock | 17,500 | 0.00 | — | 33,782 | D | ↗ |
| 2025-03-04 | Rothfuss Cristin | Officer | F-InKind | D | Common Stock | 296 | 101.34 | 30.0K | 13,325 | D | ↗ |
| 2025-03-04 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 1,704 | 101.34 | 172.7K | 65,322 | D | ↗ |
| 2025-03-04 | Murray Dallan | Officer | F-InKind | D | Common Stock | 1,685 | 101.34 | 170.8K | 19,821 | D | ↗ |
| 2025-03-04 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 1,370 | 101.34 | 138.8K | 44,956 | D | ↗ |
| 2025-03-04 | Arif Bilal | Officer | F-InKind | D | Common Stock | 281 | 101.34 | 28.5K | 16,515 | D | ↗ |
| 2025-03-03 | Rothfuss Cristin | Officer | F-InKind | D | Common Stock | 391 | 103.77 | 40.6K | 13,621 | D | ↗ |
| 2025-03-03 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 715 | 103.77 | 74.2K | 67,026 | D | ↗ |
| 2025-03-03 | Murray Dallan | Officer | F-InKind | D | Common Stock | 711 | 103.77 | 73.8K | 21,506 | D | ↗ |
| 2025-03-03 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 557 | 103.77 | 57.8K | 46,326 | D | ↗ |
| 2025-03-03 | Arif Bilal | Officer | F-InKind | D | Common Stock | 719 | 103.77 | 74.6K | 16,796 | D | ↗ |
| 2025-03-01 | Wong Ryan Ho-Yan | Officer | — | — | Stock Option (Right to buy) | 2,954 | 128.67 | 380.1K | 0 | D | ↗ |
| 2025-03-01 | Rothfuss Cristin | Officer | — | — | Stock Option (Right to buy) | 6,200 | 128.67 | 797.8K | 0 | D | ↗ |
| 2025-03-01 | Murray Dallan | Officer | — | D | Stock Option (Right to buy) | 11,723 | 128.67 | 1.51M | 0 | — | ↗ |
| 2025-02-11 | Rodino-Klapac Louise | Officer | A-Award | A | Performance Restricted Stock Units | 3,500 | 0.00 | — | 17,500 | D | ↗ |
| 2025-02-11 | Murray Dallan | Officer | A-Award | A | Performance Restricted Stock Units | 3,500 | 0.00 | — | 17,500 | D | ↗ |
| 2025-02-11 | Estepan Ian Michael | Officer | A-Award | A | Performance Restricted Stock Units | 3,500 | 0.00 | — | 17,500 | D | ↗ |
| 2025-02-11 | Arif Bilal | Officer | A-Award | A | Performance Restricted Stock Units | 3,500 | 0.00 | — | 17,500 | D | ↗ |
| 2025-01-29 | Estepan Ian Michael | Officer | M-Exempt | A | Common Stock | 1,533 | 12.00 | 18.4K | 49,496 | D | ↗ |
| 2024-12-27 | Estepan Ian Michael | Officer | G-Gift | D | Common Stock | 250 | 0.00 | — | 33,696 | D | ↗ |
| 2024-12-12 | Wigzell Hans Lennart Rudolf | Director | M-Exempt | A | Common Stock | 10,500 | 13.71 | 144.0K | 33,340 | D | ↗ |
| 2024-12-05 | Boor Kathryn Jean | Director | S-Sale | D | Common Stock | 1,636 | 125.55 | 205.4K | 5,880 | D | ↗ |
| 2024-11-26 | Rothfuss Cristin | Officer | A-Award | A | Common Stock | 2,000 | 0.00 | — | 13,817 | D | ↗ |
| 2024-11-18 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 4,558 | 102.89 | 469.0K | 67,630 | D | ↗ |
| 2024-09-12 | Connelly Deirdre P | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-04 | BEHRENS M KATHLEEN | Director | G-Gift | D | Common Stock | 746 | 0.00 | — | 191,093 | — | ↗ |
| 2024-08-30 | Estepan Ian Michael | Officer | S-Sale | D | Common Stock | 5,985 | 137.36 | 822.1K | 33,946 | — | ↗ |
| 2024-08-16 | Chambers Michael Andrew | Director | P-Purchase | A | Common Stock | 18,284 | 134.06 | 2.45M | 278,386 | — | ↗ |
| 2024-07-03 | BEHRENS M KATHLEEN | Director | M-Exempt | A | Common Stock | 15,000 | 13.90 | 208.5K | 191,839 | — | ↗ |
| 2024-06-25 | Brown Ryan Edward | Officer | S-Sale | D | Common Stock | 975 | 160.31 | 156.3K | 45,267 | — | ↗ |
| 2024-06-25 | Arif Bilal | Officer | S-Sale | D | Common Stock | 3,898 | 163.23 | 636.3K | 17,363 | — | ↗ |
| 2024-06-24 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 2,182 | 164.64 | 359.2K | 72,141 | — | ↗ |
| 2024-06-24 | Murray Dallan | Officer | F-InKind | D | Common Stock | 2,352 | 164.64 | 387.2K | 22,023 | — | ↗ |
| 2024-06-24 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 2,483 | 164.64 | 408.8K | 39,931 | — | ↗ |
| 2024-06-24 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 2,352 | 164.64 | 387.2K | 32,586 | — | ↗ |
| 2024-06-24 | Arif Bilal | Officer | S-Sale | D | Common Stock | 5,580 | 162.31 | 905.7K | 23,540 | — | ↗ |
| 2024-06-21 | Rodino-Klapac Louise | Officer | A-Award | A | Performance Stock Units | 6,250 | 0.00 | — | 6,250 | — | ↗ |
| 2024-06-21 | Murray Dallan | Officer | M-Exempt | D | Performance Stock Units | 6,250 | 0.00 | — | 0 | — | ↗ |
| 2024-06-21 | Estepan Ian Michael | Officer | M-Exempt | D | Performance Stock Units | 6,250 | 0.00 | — | 0 | — | ↗ |
| 2024-06-21 | Brown Ryan Edward | Officer | M-Exempt | D | Performance Stock Units | 6,250 | 0.00 | — | 0 | — | ↗ |
| 2024-06-21 | Arif Bilal | Officer | M-Exempt | A | Common Stock | 6,250 | 0.00 | — | 31,472 | — | ↗ |
| 2024-05-02 | Murray Dallan | Officer | S-Sale | D | Common Stock | 3,635 | 140.00 | 508.9K | 18,125 | — | ↗ |
| 2024-04-24 | Murray Dallan | Officer | — | D | Common Stock | 0 | 0.00 | — | 21,760 | — | ↗ |
| 2024-03-11 | Boor Kathryn Jean | Director | S-Sale | D | Common Stock | 761 | 122.93 | 93.5K | 7,516 | — | ↗ |
| 2024-03-08 | Wigzell Hans Lennart Rudolf | Director | S-Sale | D | Common Stock | 3,155 | 123.85 | 390.7K | 34,685 | — | ↗ |
| 2024-03-08 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 909 | 123.14 | 111.9K | 68,073 | — | ↗ |
| 2024-03-08 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 1,035 | 123.14 | 127.4K | 36,164 | — | ↗ |
| 2024-03-08 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 899 | 123.14 | 110.7K | 28,688 | — | ↗ |
| 2024-03-08 | Arif Bilal | Officer | F-InKind | D | Common Stock | 472 | 123.14 | 58.1K | 25,222 | — | ↗ |
| 2024-03-07 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 512 | 120.49 | 61.7K | 68,982 | — | ↗ |
| 2024-03-07 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 526 | 120.49 | 63.4K | 37,199 | — | ↗ |
| 2024-03-07 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 506 | 120.49 | 61.0K | 29,587 | — | ↗ |
| 2024-03-07 | Arif Bilal | Officer | F-InKind | D | Common Stock | 506 | 120.49 | 61.0K | 25,694 | — | ↗ |
| 2024-03-06 | Wong Ryan Ho-Yan | Officer | — | — | Stock Option (Right to buy) | 3,266 | 155.99 | 509.5K | 0 | D | ↗ |
| 2024-03-06 | Rothfuss Cristin | Officer | — | — | Stock Option (Right to buy) | 5,900 | 155.99 | 920.3K | 0 | D | ↗ |
| 2024-03-06 | Murray Dallan | Officer | — | D | Stock Option (Right to buy) | 26,359 | 155.99 | 4.11M | 0 | — | ↗ |
| 2024-03-05 | Mayo Stephen | Director | S-Sale | D | Common Stock | 3,135 | 122.96 | 385.5K | 6,621 | — | ↗ |
| 2024-03-04 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 1,728 | 125.32 | 216.6K | 69,494 | — | ↗ |
| 2024-03-04 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 1,389 | 125.32 | 174.1K | 37,725 | — | ↗ |
| 2024-03-04 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 1,734 | 125.32 | 217.3K | 30,093 | — | ↗ |
| 2024-03-04 | Arif Bilal | Officer | F-InKind | D | Common Stock | 237 | 125.32 | 29.7K | 26,200 | — | ↗ |
| 2024-03-01 | Wigzell Hans Lennart Rudolf | Director | A-Award | A | Common Stock | 1,846 | 0.00 | — | 22,840 | — | ↗ |
| 2024-03-01 | Rodino-Klapac Louise | Officer | A-Award | A | Stock Option (right to buy) | 12,500 | 128.67 | 1.61M | 12,500 | — | ↗ |
| 2024-03-01 | Nicaise Claude | Director | A-Award | A | Stock Option (right to buy) | 3,679 | 128.67 | 473.4K | 3,679 | — | ↗ |
| 2024-03-01 | Mayo Stephen | Director | A-Award | A | Stock Option (right to buy) | 3,679 | 128.67 | 473.4K | 3,679 | — | ↗ |
| 2024-03-01 | Estepan Ian Michael | Officer | A-Award | D | Stock Option (right to buy) | 12,500 | 128.67 | 1.61M | 12,500 | — | ↗ |
| 2024-03-01 | Chambers Michael Andrew | Director | A-Award | A | Common Stock | 1,846 | 0.00 | — | 8,277 | — | ↗ |
| 2024-03-01 | Brown Ryan Edward | Officer | A-Award | D | Stock Option (right to buy) | 12,500 | 128.67 | 1.61M | 12,500 | — | ↗ |
| 2024-03-01 | Boor Kathryn Jean | Director | A-Award | A | Stock Option (right to buy) | 3,679 | 128.67 | 473.4K | 3,679 | — | ↗ |
| 2024-03-01 | Barry Richard | Director | A-Award | A | Stock Option (right to buy) | 3,679 | 128.67 | 473.4K | 3,679 | — | ↗ |
| 2024-03-01 | BEHRENS M KATHLEEN | Director | A-Award | A | Stock Option (right to buy) | 3,679 | 128.67 | 473.4K | 3,679 | — | ↗ |
| 2024-03-01 | Arif Bilal | Officer | S-Sale | D | Common Stock | 457 | 129.71 | 59.3K | 26,836 | — | ↗ |
| 2023-12-01 | Arif Bilal | Officer | F-InKind | D | Common Stock | 3,682 | 80.34 | 295.8K | 22,886 | — | ↗ |
| 2023-11-30 | Wong Ryan Ho-Yan | Officer | — | — | Stock Option (Right to buy) | 583 | 122.81 | 71.6K | 0 | D | ↗ |
| 2023-11-17 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 4,508 | 82.98 | 374.1K | 65,751 | — | ↗ |
| 2023-11-03 | INGRAM DOUGLAS S | Director / Officer | P-Purchase | A | Common Stock | 10,081 | 78.57 | 792.1K | 375,163 | — | ↗ |
| 2023-11-03 | Barry Richard | Director | P-Purchase | A | Common Stock | 10,000 | 78.81 | 788.1K | 10,000 | — | ↗ |
| 2023-11-03 | BEHRENS M KATHLEEN | Director | M-Exempt | A | Common Stock | 15,000 | 29.03 | 435.5K | 174,993 | — | ↗ |
| 2023-08-14 | Chambers Michael Andrew | Director | P-Purchase | A | Common Stock | 4,032 | 109.89 | 443.1K | 246,996 | — | ↗ |
| 2023-08-11 | Chambers Michael Andrew | Director | P-Purchase | A | Common Stock | 23,686 | 108.05 | 2.56M | 237,017 | — | ↗ |
| 2023-08-10 | Chambers Michael Andrew | Director | P-Purchase | A | Common Stock | 1,091 | 105.90 | 115.5K | 181,761 | — | ↗ |
| 2023-08-04 | Wigzell Hans Lennart Rudolf | Director | M-Exempt | D | Stock Option (right to buy) | 15,000 | 29.03 | 435.5K | 0 | — | ↗ |
| 2023-06-01 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 89 | 123.60 | 11.0K | 28,096 | — | ↗ |
| 2023-03-30 | Arif Bilal | Officer | F-InKind | D | Common Stock | 307 | 136.66 | 42.0K | 26,367 | — | ↗ |
| 2023-03-08 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 912 | 153.19 | 139.7K | 70,170 | — | ↗ |
| 2023-03-08 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 744 | 153.19 | 114.0K | 34,679 | — | ↗ |
| 2023-03-08 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 635 | 153.19 | 97.3K | 28,185 | — | ↗ |
| 2023-03-08 | Arif Bilal | Officer | F-InKind | D | Common Stock | 314 | 153.19 | 48.1K | 26,674 | — | ↗ |
| 2023-03-07 | Wong Ryan Ho-Yan | Officer | — | — | Stock Option (Right to buy) | 2,558 | 80.42 | 205.7K | 0 | D | ↗ |
| 2023-03-07 | Rothfuss Cristin | Officer | — | — | Stock Option (Right to buy) | 4,197 | 80.42 | 337.5K | 0 | D | ↗ |
| 2023-03-07 | Murray Dallan | Officer | — | D | Stock Option (Right to buy) | 46,756 | 80.42 | 3.76M | 0 | — | ↗ |
| 2023-03-07 | Arif Bilal | Officer | — | D | Stock Option (right to buy) | 8,400 | 80.42 | 675.5K | — | — | ↗ |
| 2023-03-06 | Wigzell Hans Lennart Rudolf | Director | A-Award | A | Common Stock | 1,523 | 0.00 | — | 20,994 | — | ↗ |
| 2023-03-06 | Rodino-Klapac Louise | Officer | A-Award | A | Stock Option (right to buy) | 27,000 | 155.99 | 4.21M | 27,000 | — | ↗ |
| 2023-03-06 | Nicaise Claude | Director | A-Award | A | Stock Option (right to buy) | 3,257 | 155.99 | 508.1K | 3,257 | — | ↗ |
| 2023-03-06 | Mayo Stephen | Director | A-Award | A | Stock Option (right to buy) | 3,257 | 155.99 | 508.1K | 3,257 | — | ↗ |
| 2023-03-06 | Estepan Ian Michael | Officer | A-Award | A | Stock Option (right to buy) | 27,000 | 155.99 | 4.21M | 27,000 | — | ↗ |
| 2023-03-06 | Chambers Michael Andrew | Director | A-Award | A | Common Stock | 1,523 | 0.00 | — | 6,431 | — | ↗ |
| 2023-03-06 | Brown Ryan Edward | Officer | A-Award | A | Common Stock | 4,500 | 0.00 | — | 28,820 | — | ↗ |
| 2023-03-06 | Boor Kathryn Jean | Director | A-Award | A | Stock Option (right to buy) | 3,257 | 155.99 | 508.1K | 3,257 | — | ↗ |
| 2023-03-06 | Barry Richard | Director | A-Award | A | Stock Option (right to buy) | 3,257 | 155.99 | 508.1K | 3,257 | — | ↗ |
| 2023-03-06 | BEHRENS M KATHLEEN | Director | A-Award | A | Stock Option (right to buy) | 3,257 | 155.99 | 508.1K | 3,257 | — | ↗ |
| 2023-03-06 | Arif Bilal | Officer | F-InKind | D | Common Stock | 154 | 157.21 | 24.2K | 22,488 | — | ↗ |
| 2023-03-01 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 522 | 147.57 | 77.0K | 67,716 | — | ↗ |
| 2023-03-01 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 378 | 147.57 | 55.8K | 32,293 | — | ↗ |
| 2023-03-01 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 196 | 147.57 | 28.9K | 25,645 | — | ↗ |
| 2023-03-01 | Arif Bilal | Officer | F-InKind | D | Common Stock | 80 | 147.57 | 11.8K | 22,837 | — | ↗ |
| 2022-12-31 | Arif Bilal | Officer | — | D | Common Stock | 0 | 0.00 | — | 22,917 | — | ↗ |
| 2022-12-19 | BEHRENS M KATHLEEN | Director | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 0 | — | ↗ |
| 2022-11-17 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 4,211 | 108.52 | 457.0K | 67,998 | — | ↗ |
| 2022-11-17 | Mayo Stephen | Director | S-Sale | D | Common Stock | 858 | 109.92 | 94.3K | 6,387 | — | ↗ |
| 2022-08-19 | Chambers Michael Andrew | Director | P-Purchase | A | Common Stock | 40,110 | 108.20 | 4.34M | 45,018 | — | ↗ |
| 2022-07-31 | Wong Ryan Ho-Yan | Officer | — | — | Stock Option (Right to buy) | 9,600 | 67.78 | 650.7K | 0 | D | ↗ |
| 2022-06-02 | Chambers Michael Andrew | Director | — | I | Common Stock | 0 | 0.00 | — | 75,194 | — | ↗ |
| 2022-06-02 | Boor Kathryn Jean | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-01 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 54 | 72.67 | 3.9K | 25,841 | — | ↗ |
| 2022-03-07 | Wigzell Hans Lennart Rudolf | Director | A-Award | A | Common Stock | 2,953 | 0.00 | — | 19,471 | — | ↗ |
| 2022-03-07 | Nicaise Claude | Director | A-Award | A | Stock Option (right to buy) | 5,077 | 80.42 | 408.3K | 5,077 | — | ↗ |
| 2022-03-07 | Mayo Stephen | Director | A-Award | A | Stock Option (right to buy) | 5,077 | 0.00 | — | 5,077 | — | ↗ |
| 2022-03-07 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 5,077 | 80.42 | 408.3K | 5,077 | — | ↗ |
| 2022-03-07 | Estepan Ian Michael | Officer | A-Award | A | Common Stock | 8,000 | 0.00 | — | 32,671 | — | ↗ |
| 2022-03-07 | Barry Richard | Director | A-Award | A | Common Stock | 2,953 | 0.00 | — | 2,928,319 | — | ↗ |
| 2022-03-07 | BEHRENS M KATHLEEN | Director | A-Award | A | Stock Option (right to buy) | 5,077 | 0.00 | — | 5,077 | — | ↗ |
| 2022-03-04 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 1,216 | 79.20 | 96.3K | 64,111 | — | ↗ |
| 2022-03-04 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 1,308 | 79.20 | 103.6K | 25,069 | — | ↗ |
| 2022-03-04 | Ciambrone William | Officer | F-InKind | D | Common Stock | 1,160 | 79.20 | 91.9K | 14,099 | — | ↗ |
| 2022-03-04 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 153 | 79.36 | 12.1K | 17,895 | — | ↗ |
| 2022-03-03 | Rothfuss Cristin | Officer | — | — | Stock Option (Right to buy) | 1,248 | 87.11 | 108.7K | 0 | D | ↗ |
| 2022-03-03 | Murray Dallan | Officer | — | D | Stock Option (Right to buy) | 58,852 | 87.11 | 5.13M | 0 | — | ↗ |
| 2022-03-01 | Rodino-Klapac Louise | Officer | F-InKind | D | Common Stock | 572 | 75.05 | 42.9K | 65,327 | — | ↗ |
| 2022-03-01 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 376 | 75.05 | 28.2K | 26,377 | — | ↗ |
| 2022-03-01 | Brown Ryan Edward | Officer | F-InKind | D | Common Stock | 184 | 75.05 | 13.8K | 19,184 | — | ↗ |
| 2021-12-15 | BEHRENS M KATHLEEN | Director | M-Exempt | A | Common Stock | 5,000 | 10.08 | 50.4K | 135,517 | — | ↗ |
| 2021-12-14 | Murray Dallan | Officer | — | D | Stock Option (Right to buy) | 24,562 | 169.54 | 4.16M | 0 | — | ↗ |
| 2021-12-10 | GRAY MARY ANN | Director | M-Exempt | A | Common Stock | 967 | 0.00 | — | 9,403 | — | ↗ |
| 2021-11-24 | Rodino-Klapac Louise | Officer | P-Purchase | A | Common Stock | 3,780 | 79.33 | 299.9K | 65,678 | — | ↗ |
| 2021-11-17 | INGRAM DOUGLAS S | Director / Officer | P-Purchase | A | Common Stock | 25,026 | 79.94 | 2.00M | 365,082 | — | ↗ |
| 2021-11-16 | Rodino-Klapac Louise | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 61,898 | — | ↗ |
| 2021-11-16 | Mayo Stephen | Director | A-Award | A | Stock Option (right to buy) | 8,238 | 83.00 | 683.8K | 8,238 | — | ↗ |
| 2021-09-08 | Estepan Ian Michael | Officer | F-InKind | D | Common Stock | 1,623 | 78.29 | 127.1K | 26,753 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-504.7K
Shares Outstanding
104.99M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Douglas S. Ingram Chief Executive Officer | 1.17M | — | 6.00M | — | 649.0K | 20.2K | 7.84M | 76.52% | ↗ |
| 2 | 2025 | Louise Rodino-Klapac, Ph.D. President, Research and Development and Technical Operations | 752.5K | — | 2.60M | 822.9K | 260.0K | 16.9K | 4.46M | 76.90% | ↗ |
| 3 | 2025 | Ian M. Estepan President, Chief Operating Officer | 740.5K | — | 2.60M | 822.9K | 260.0K | 17.0K | 4.44M | 77.10% | ↗ |
| 4 | 2025 | Cristin L. Rothfuss Executive Vice President, General Counsel Former Officer | 629.9K | — | 2.60M | 822.9K | 159.5K | 17.5K | 4.23M | 80.94% | ↗ |
| 5 | 2025 | Ryan H. Wong Executive Vice President, Chief Financial Officer | 480.1K | — | 2.18M | 399.0K | 137.5K | 16.3K | 3.21M | 80.26% | ↗ |
| 6 | 2025 | Dallan Murray Former Executive Vice President, Chief Customer Officer | 373.1K | — | 825.0K | 822.9K | — | 721.8K | 2.74M | 60.08% | ↗ |
| 7 | 2024 | Ian M. Estepan Executive Vice President, Chief Financial Officer | 657.0K | — | 772.0K | 845.3K | 430.2K | 48.1K | 2.75M | 58.76% | ↗ |
| 8 | 2024 | Ian M. Estepan President, Chief Operating Officer | 657.0K | — | 772.0K | 845.3K | 430.2K | 48.1K | 2.75M | 58.76% | ↗ |
| 9 | 2024 | Louise Rodino-Klapac, Ph.D. Executive Vice President, Head of R&D, Chief Scientific Officer | 666.7K | — | 772.0K | 845.3K | 436.6K | 16.7K | 2.74M | 59.08% | ↗ |
| 10 | 2024 | Louise Rodino-Klapac, Ph.D. President, Research and Development and Technical Operations | 666.7K | — | 772.0K | 845.3K | 436.6K | 16.7K | 2.74M | 59.08% | ↗ |
| 11 | 2024 | Dallan Murray Executive Vice President, Chief Customer Officer Former Officer | 621.8K | — | 772.0K | 845.3K | 409.4K | 17.8K | 2.67M | 60.66% | ↗ |
| 12 | 2024 | Dallan Murray Former Executive Vice President, Chief Customer Officer | 621.8K | — | 772.0K | 845.3K | 409.4K | 17.8K | 2.67M | 60.66% | ↗ |
| 13 | 2024 | Ryan E. Brown Former Executive Vice President, Chief General Counsel and Corporate Secretary | 589.3K | — | 772.0K | 845.3K | 387.7K | 16.9K | 2.61M | 61.94% | ↗ |
| 14 | 2024 | Bilal Arif Executive Vice President, Chief Technical Operations Officer | 545.2K | — | 772.0K | 845.3K | 358.3K | 18.4K | 2.54M | 63.69% | ↗ |
| 15 | 2024 | Douglas S. Ingram Chief Executive Officer | 846.9K | — | — | — | 1.11M | 20.0K | 1.98M | 0.00% | ↗ |
| 16 | 2024 | Douglas S. Ingram President and Chief Executive Officer | 846.9K | — | — | — | 1.11M | 20.0K | 1.98M | 0.00% | ↗ |
| 17 | 2023 | Louise Rodino-Klapac, Ph.D. Executive Vice President, Head of R&D, Chief Scientific Officer | 641.1K | — | 702.0K | 1.99M | 371.4K | 15.7K | 3.72M | 72.35% | ↗ |
| 18 | 2023 | Louise Rodino-Klapac, Ph.D. President, Research and Development and Technical Operations | 641.1K | — | 702.0K | 1.99M | 371.4K | 15.7K | 3.72M | 72.35% | ↗ |
| 19 | 2023 | Ian M. Estepan President, Chief Operating Officer | 618.5K | — | 702.0K | 1.99M | 365.9K | 30.3K | 3.71M | 72.62% | ↗ |
| 20 | 2023 | Ian M. Estepan Executive Vice President, Chief Financial Officer | 618.5K | — | 702.0K | 1.99M | 365.9K | 30.3K | 3.71M | 72.62% | ↗ |
| 21 | 2023 | Ryan E. Brown Executive Vice President, Chief General Counsel | 550.2K | — | 702.0K | 1.99M | 321.4K | 15.9K | 3.58M | 75.20% | ↗ |
| 22 | 2023 | Ryan E. Brown Former Executive Vice President, Chief General Counsel and Corporate Secretary | 550.2K | — | 702.0K | 1.99M | 321.4K | 15.9K | 3.58M | 75.20% | ↗ |
| 23 | 2023 | Bilal Arif Executive Vice President, Chief Technical Operations Officer | 514.1K | — | 702.0K | 1.99M | 299.0K | 16.6K | 3.52M | 76.43% | ↗ |
| 24 | 2023 | Douglas S. Ingram Chief Executive Officer | 799.8K | — | — | — | 842.5K | 19.0K | 1.66M | 0.00% | ↗ |
| 25 | 2023 | Douglas S. Ingram President and Chief Executive Officer | 799.8K | — | — | — | 842.5K | 19.0K | 1.66M | 0.00% | ↗ |
| 26 | 2022 | Douglas S. Ingram President and Chief Executive Officer | 740.0K | — | — | 123.31M | 865.8K | 18.0K | 124.94M | 98.70% | ↗ |
| 27 | 2022 | Douglas Ingram President and Chief Executive Officer | 740.0K | — | — | 124.94M | 865.8K | 18.0K | 124.94M | 100.00% | ↗ |
| 28 | 2022 | William Ciambrone Executive Vice President, Technical Operations | 514.3K | — | 3.08M | 9.97M | 336.5K | 16.7K | 6.96M | 187.53% | ↗ |
| 29 | 2022 | Louise Rodino-Klapac, Ph.D. Executive Vice President, Head of R&D, Chief Scientific Officer | 617.0K | — | 643.4K | 2.26M | 403.7K | 14.7K | 3.94M | 73.73% | ↗ |
| 30 | 2022 | Ian M. Estepan Executive Vice President, Chief Financial Officer | 539.8K | — | 643.4K | 2.26M | 353.2K | 24.5K | 3.82M | 76.01% | ↗ |
| 31 | 2022 | Ryan Brown Executive Vice President, General Counsel | 508.0K | — | 643.4K | 5.99M | 300.6K | 14.8K | 3.73M | 177.92% | ↗ |
| 32 | 2022 | Ryan E. Brown Former Executive Vice President, Chief General Counsel and Corporate Secretary | 508.0K | — | 643.4K | 2.26M | 300.6K | 14.8K | 3.73M | 77.92% | ↗ |
| 33 | 2022 | Ryan E. Brown Executive Vice President, Chief General Counsel | 508.0K | — | 643.4K | 2.26M | 300.6K | 14.8K | 3.73M | 77.92% | ↗ |
| 34 | 2021 | Louise Rodino-Klapac, Ph.D. Executive Vice President, Head of R&D, Chief Scientific Officer | 555.6K | — | 4.63M | 2.96M | 360.0K | 14.1K | 8.52M | 89.08% | ↗ |
| 35 | 2021 | Ian M. Estepan Executive Vice President, Chief Financial Officer | 525.0K | — | 1.31M | 2.96M | 315.0K | 21.7K | 5.13M | 83.19% | ↗ |
| 36 | 2021 | Ryan Brown Senior Vice President General Counsel Former Officer | 473.6K | — | 1.31M | 2.96M | 260.8K | 104.0K | 5.10M | 83.58% | ↗ |
| 37 | 2021 | Ryan E. Brown Executive Vice President, Chief General Counsel | 473.6K | — | 1.31M | 2.96M | 260.8K | 104.0K | 5.10M | 83.58% | ↗ |
| 38 | 2021 | Ryan Brown Executive Vice President, General Counsel | 473.6K | — | 1.31M | 2.96M | 260.8K | 104.0K | 5.10M | 83.58% | ↗ |
| 39 | 2021 | William Ciambrone Executive Vice President, Technical Operations | 494.1K | — | 1.31M | 2.96M | 270.1K | 16.1K | 5.05M | 84.54% | ↗ |
| 40 | 2021 | Douglas Ingram President and Chief Executive Officer | 729.7K | — | — | — | 799.2K | 17.4K | 1.55M | 0.00% | ↗ |
| 41 | 2021 | Douglas S. Ingram President and Chief Executive Officer | 729.7K | — | — | — | 799.2K | 17.4K | 1.55M | 0.00% | ↗ |
| 42 | 2020 | Gilmore O'Neill, M.B., M.M.Sc. Executive Vice President, Chief Medical Officer | 599.8K | — | 1.75M | 4.31M | 302.0K | 619.3K | 7.58M | 79.92% | ↗ |
| 43 | 2020 | Louise Rodino-Klapac, Ph.D. Executive Vice President, Head of R&D, Chief Scientific Officer | 495.6K | — | 766.9K | 5.76M | 229.9K | 13.9K | 7.27M | 89.83% | ↗ |
| 44 | 2020 | Louise Rodino-Klapac, Ph.D. Executive Vice President, Chief Scientific Officer | 495.6K | — | 766.9K | 5.76M | 229.9K | 13.5K | 7.27M | 89.83% | ↗ |
| 45 | 2020 | David Tyronne Howton, Jr. Executive Vice President, General Counsel and Corporate Secretary | 470.7K | — | 1.05M | 3.80M | 221.6K | 157.3K | 5.70M | 85.10% | ↗ |
| 46 | 2020 | Ian M. Estepan Executive Vice President, Chief Financial Officer | 445.8K | — | 435.0K | 4.06M | 205.5K | 32.9K | 5.18M | 86.79% | ↗ |
| 47 | 2020 | Gilmore O'Neill, M.B., M.M.Sc. Executive Vice President, Chief Scientific Officer | 583.3K | — | 766.9K | 2.13M | 293.2K | 15.5K | 3.79M | 76.47% | ↗ |
| 48 | 2020 | Sandesh Mahatme Executive Vice President, Chief Financial Officer and Chief Business Officer | 312.8K | — | 766.9K | 2.24M | — | 39.4K | 3.36M | 89.53% | ↗ |
| 49 | 2020 | Douglas S. Ingram President and Chief Executive Officer | 669.3K | — | — | — | 605.5K | 17.2K | 1.29M | 0.00% | ↗ |
| 50 | 2020 | Douglas Ingram President and Chief Executive Officer | 669.3K | — | — | — | 605.5K | 17.2K | 1.29M | 0.00% | ↗ |
| 51 | 2020 | Joseph Bratica Vice President, Corporate Controller Former Officers | 326.0K | — | 237.5K | 235.8K | 100.8K | 11.6K | 911.9K | 51.91% | ↗ |
| 52 | 2020 | William Ciambrone Executive Vice President, Technical Operations | 458.2K | — | — | — | 207.3K | 15.0K | 680.4K | 0.00% | ↗ |
| 53 | 2019 | Gilmore O'Neill, M.B., M.M.Sc. Executive Vice President, Chief Scientific Officer | 564.0K | — | — | 4.23M | 354.1K | 15.3K | 5.17M | 81.94% | ↗ |
| 54 | 2019 | Sandesh Mahatme Executive Vice President, Chief Financial Officer and Chief Business Officer | 557.3K | — | — | 4.23M | 354.3K | 14.8K | 5.16M | 82.05% | ↗ |
| 55 | 2019 | William Ciambrone Executive Vice President, Technical Operations | 51.3K | — | — | 4.29M | — | 1.0K | 4.35M | 98.80% | ↗ |
| 56 | 2019 | David Tyronne Howton, Jr. Executive Vice President, General Counsel and Corporate Secretary | 458.8K | — | — | 3.46M | 259.6K | 13.3K | 4.20M | 82.56% | ↗ |
| 57 | 2019 | Gilmore O'Neill, M.B., M.M.Sc. Executive Vice President, Chief Medical Officer | 583.3K | — | 766.9K | 2.13M | 293.2K | 15.5K | 3.79M | 76.47% | ↗ |
| 58 | 2019 | Douglas Ingram President and Chief Executive Officer | 650.0K | — | — | — | 731.3K | 5.8K | 1.39M | 0.00% | ↗ |
| 59 | 2019 | Douglas S. Ingram President and Chief Executive Officer | 650.0K | — | — | — | 731.3K | 5.8K | 1.39M | 0.00% | ↗ |
| 60 | 2018 | Gilmore O'Neill, M.B., M.M.Sc. Executive Vice President, Chief Scientific Officer | 311.0K | — | 1.15M | 4.77M | 213.4K | 2.1K | 6.45M | 91.84% | ↗ |
| 61 | 2018 | Gilmore O'Neill, M.B., M.M.Sc. Executive Vice President, Chief Medical Officer | 564.0K | — | — | 4.23M | 354.1K | 15.3K | 5.17M | 81.94% | ↗ |
| 62 | 2018 | Sandesh Mahatme Executive Vice President, Chief Financial Officer and Chief Business Officer | 498.1K | — | — | 3.36M | 335.9K | 24.8K | 4.22M | 79.64% | ↗ |
| 63 | 2018 | David Tyronne Howton, Jr. Executive Vice President, General Counsel and Corporate Secretary | 438.2K | — | — | 2.41M | 265.6K | 13.1K | 3.13M | 77.09% | ↗ |
| 64 | 2018 | Alexander Cumbo Executive Vice President, Chief Commercial Officer | 428.2K | — | — | 2.41M | 261.5K | 12.9K | 3.12M | 77.44% | ↗ |
| 65 | 2018 | Douglas Ingram President and Chief Executive Officer | 650.0K | — | — | — | 778.1K | 5.8K | 1.43M | 0.00% | ↗ |
| 66 | 2018 | Douglas S. Ingram President and Chief Executive Officer | 650.0K | — | — | — | 778.1K | 5.8K | 1.43M | 0.00% | ↗ |
| 67 | 2017 | Douglas Ingram President and Chief Executive Officer | 337.5K | — | 11.61M | 44.48M | 420.9K | 16.1K | 56.87M | 98.64% | ↗ |
| 68 | 2017 | Edward M. Kaye, M.D. Former President and Chief Executive Officer | 346.9K | — | 2.31M | 1.60M | — | 513.7K | 4.78M | 81.99% | ↗ |
| 69 | 2017 | Guriqbal Basi Senior Vice President, Chief Scientific Officer | 105.0K | — | — | 2.17M | 72.8K | 14.3K | 2.37M | 91.88% | ↗ |
| 70 | 2017 | Alexander Cumbo Executive Vice President, Chief Commercial Officer | 353.6K | — | 636.4K | 1.10M | 212.8K | 11.8K | 2.32M | 75.06% | ↗ |
| 71 | 2017 | Alexander Cumbo Senior Vice President, Chief Commercial Officer | 353.6K | — | 636.4K | 1.10M | 212.8K | 11.8K | 2.32M | 75.06% | ↗ |
| 72 | 2017 | Sandesh Mahatme Executive Vice President, Chief Financial Officer and Chief Business Officer | 459.3K | — | 867.8K | 601.4K | 257.2K | 14.4K | 2.20M | 66.78% | ↗ |
| 73 | 2017 | David Tyronne Howton, Jr. Senior Vice President, General Counsel and Corporate Secretary | 407.2K | — | 694.3K | 481.1K | 228.0K | 12.9K | 1.82M | 64.46% | ↗ |
| 74 | 2017 | David Tyronne Howton, Jr. Executive Vice President, General Counsel and Corporate Secretary | 407.2K | — | 694.3K | 481.1K | 228.0K | 12.9K | 1.82M | 64.46% | ↗ |
| 75 | 2017 | Catherine Stehman-Breen Former Senior Vice President, Chief Medical Officer | 288.2K | — | — | 1.45M | — | 65.4K | 1.80M | 80.36% | ↗ |
| 76 | 2016 | Edward M. Kaye, M.D. Former President and Chief Executive Officer | 532.1K | — | 64.5K | 2.39M | 429.0K | 18.2K | 3.43M | 71.44% | ↗ |
| 77 | 2016 | Edward M. Kaye, M.D. President and Chief Executive Officer | 532.1K | — | 64.5K | 2.39M | 429.0K | 18.2K | 3.43M | 71.44% | ↗ |
| 78 | 2016 | Sandesh Mahatme Executive Vice President, Chief Financial Officer and Chief Business Officer | 459.3K | — | 1.24M | 894.5K | 220.4K | 24.4K | 2.84M | 75.18% | ↗ |
| 79 | 2016 | David Tyronne Howton, Jr. Executive Vice President, General Counsel and Corporate Secretary | 407.2K | — | 996.6K | 715.6K | 195.4K | 12.7K | 2.33M | 73.56% | ↗ |
| 80 | 2016 | David Tyronne Howton, Jr. Senior Vice President, General Counsel and Corporate Secretary | 407.2K | — | 996.6K | 715.6K | 195.4K | 12.7K | 2.33M | 73.56% | ↗ |
| 81 | 2016 | Shamim Ruff Senior Vice President, Regulatory Affairs and Quality | 356.1K | — | 877.2K | 596.3K | 170.9K | 15.6K | 2.02M | 73.09% | ↗ |
| 82 | 2016 | Alexander Cumbo Senior Vice President, Chief Commercial Officer | 314.2K | — | 846.6K | 477.0K | 152.4K | 11.6K | 1.80M | 73.46% | ↗ |
| 83 | 2016 | Alexander Cumbo Executive Vice President, Chief Commercial Officer | 314.2K | — | 846.6K | 477.0K | 152.4K | 11.6K | 1.80M | 73.46% | ↗ |
| 84 | 2016 | Alexander Cumbo Senior Vice President, Global Commercial Operations | 314.2K | — | 846.6K | 477.0K | 152.4K | 11.6K | 1.80M | 73.46% | ↗ |
| 85 | 2015 | Christopher Garabedian Former President and Chief Executive Officer | 152.6K | — | — | 3.88M | — | 479.8K | 4.51M | 85.98% | ↗ |
| 86 | 2015 | Edward M. Kaye, M.D. Former President and Chief Executive Officer | 494.6K | — | 1.94M | 1.69M | 249.7K | 18.2K | 4.40M | 82.66% | ↗ |
| 87 | 2015 | Edward M. Kaye, M.D. Interim Chief Executive Officer, and Senior Vice President, Chief Medical Officer | 494.6K | — | 1.94M | 1.69M | 249.7K | 18.2K | 4.40M | 82.66% | ↗ |
| 88 | 2015 | Edward M. Kaye, M.D. President and Chief Executive Officer | 494.6K | — | 1.94M | 1.69M | 249.7K | 18.2K | 4.40M | 82.66% | ↗ |
| 89 | 2015 | Sandesh Mahatme Senior Vice President, Chief Financial Officer | 456.7K | — | 371.9K | 1.31M | 165.3K | 61.2K | 2.37M | 71.11% | ↗ |
| 90 | 2015 | Sandesh Mahatme Executive Vice President, Chief Financial Officer and Chief Business Officer | 456.7K | — | 371.9K | 1.31M | 165.3K | 61.2K | 2.37M | 71.11% | ↗ |
| 91 | 2015 | David Tyronne Howton, Jr. Senior Vice President, General Counsel and Corporate Secretary | 404.9K | — | 338.1K | 894.1K | 146.6K | 12.7K | 1.80M | 68.59% | ↗ |
| 92 | 2015 | Jayant Aphale, Ph.D. Senior Vice President, Technical Operations | 345.0K | — | — | 862.9K | 124.9K | 64.4K | 1.40M | 61.76% | ↗ |
| 93 | 2014 | Christopher Garabedian Former President and Chief Executive Officer | 603.2K | — | — | 3.99M | 289.5K | 119.5K | 5.00M | 79.77% | ↗ |
| 94 | 2014 | Arthur M. Krieg, M.D. Former Senior Vice President, Chief Scientific Officer | 418.0K | — | — | 4.00M | — | 1.9K | 4.42M | 90.49% | ↗ |
| 95 | 2014 | Sandesh Mahatme Senior Vice President, Chief Financial Officer | 443.7K | — | — | 1.52M | 150.9K | 65.6K | 2.18M | 69.76% | ↗ |
| 96 | 2014 | Sandesh Mahatme Executive Vice President, Chief Financial Officer and Chief Business Officer | 443.7K | — | — | 1.52M | 150.9K | 65.6K | 2.18M | 69.76% | ↗ |
| 97 | 2014 | Edward M. Kaye, M.D. Interim Chief Executive Officer, Senior Vice President, Chief Medical Officer | 399.0K | — | — | 1.16M | 131.7K | 18.0K | 1.70M | 67.80% | ↗ |
| 98 | 2014 | Edward M. Kaye, M.D. President and Chief Executive Officer | 399.0K | — | — | 1.16M | 131.7K | 17.8K | 1.70M | 67.81% | ↗ |
| 99 | 2014 | Edward M. Kaye, M.D. Interim Chief Executive Officer, and Senior Vice President, Chief Medical Officer | 399.0K | — | — | 1.16M | 131.7K | 17.8K | 1.70M | 67.81% | ↗ |
| 100 | 2014 | David Tyronne Howton, Jr. Senior Vice President, General Counsel and Corporate Secretary | 393.4K | — | — | 1.16M | 133.8K | 12.5K | 1.69M | 68.16% | ↗ |
| 101 | 2014 | Jayant Aphale, Ph.D. Senior Vice President, Technical Operations | 335.9K | — | — | 735.1K | 131.7K | 72.5K | 1.28M | 57.65% | ↗ |
| 102 | 2013 | Christopher Garabedian President and Chief Executive Officer | 580.0K | — | — | 8.58M | 362.5K | 182.0K | 9.70M | 88.41% | ↗ |
| 103 | 2013 | Christopher Garabedian Former President and Chief Executive Officer | 580.0K | — | — | 8.58M | 362.5K | 182.0K | 9.70M | 88.41% | ↗ |
| 104 | 2013 | Sandesh Mahatme Senior Vice President, Chief Financial Officer | 427.2K | 30.0K | — | 3.13M | 213.9K | 78.5K | 3.88M | 80.67% | ↗ |
| 105 | 2013 | Edward M. Kaye, M.D. Senior Vice President, Chief Medical Officer | 377.7K | — | — | 2.09M | 167.2K | 17.8K | 2.65M | 78.76% | ↗ |
| 106 | 2013 | Edward M. Kaye, M.D. Interim Chief Executive Officer, and Senior Vice President, Chief Medical Officer | 377.7K | — | — | 2.09M | 167.2K | 17.8K | 2.65M | 78.76% | ↗ |
| 107 | 2013 | Edward M. Kaye, M.D. Interim Chief Executive Officer, Senior Vice President, Chief Medical Officer | 377.7K | — | — | 2.09M | 167.2K | 17.8K | 2.65M | 78.76% | ↗ |
| 108 | 2013 | David Tyronne Howton, Jr. Senior Vice President, General Counsel and Corporate Secretary | 376.9K | — | — | 2.09M | 165.2K | 12.5K | 2.64M | 79.00% | ↗ |
| 109 | 2013 | David Tyronne Howton Senior Vice President, General Counsel and Corporate Secretary | 376.9K | — | — | 2.09M | 165.2K | 12.3K | 2.64M | 79.01% | ↗ |
| 110 | 2013 | Jayant Aphale, Ph.D. Senior Vice President, Technical Operations | 320.5K | — | — | 2.09M | 141.7K | 49.7K | 2.60M | 80.30% | ↗ |
| 111 | 2013 | Arthur M. Krieg, M.D. Former Senior Vice President, Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 112 | 2012 | Sandesh Mahatme Senior Vice President, Chief Financial Officer | 67.8K | 130.0K | — | 4.60M | 37.6K | 598.00 | 4.84M | 95.12% | ↗ |
| 113 | 2012 | David Tyronne Howton Senior Vice President, General Counsel and Corporate Secretary | 59.9K | — | — | 2.76M | 29.0K | 459.00 | 2.85M | 96.87% | ↗ |
| 114 | 2012 | David Tyronne Howton, Jr. Senior Vice President, General Counsel and Corporate Secretary | 59.9K | — | — | 2.76M | 29.0K | 459.00 | 2.85M | 96.87% | ↗ |
| 115 | 2012 | Christopher Garabedian President and Chief Executive Officer | 490.0K | — | 73.5K | 1.74M | 318.5K | 16.8K | 2.64M | 68.75% | ↗ |
| 116 | 2012 | Christopher Garabedian Former President and Chief Executive Officer | 490.0K | — | 73.5K | 1.74M | 318.5K | 16.8K | 2.64M | 68.75% | ↗ |
| 117 | 2012 | Christopher Garabedian President and Chief Executive Officer | 490.0K | — | 73.5K | 1.74M | 318.5K | 16.8K | 2.64M | 68.75% | ↗ |
| 118 | 2012 | Edward M. Kaye, M.D. Interim Chief Executive Officer, Senior Vice President, Chief Medical Officer | 364.0K | — | — | 613.6K | 165.6K | 10.7K | 1.15M | 53.18% | ↗ |
| 119 | 2012 | Edward M. Kaye, M.D. Senior Vice President, Chief Medical Officer | 364.0K | — | — | 613.6K | 165.6K | 10.7K | 1.15M | 53.18% | ↗ |
| 120 | 2012 | Edward M. Kaye, M.D. Senior Vice President, Chief Medical Officer | 364.0K | — | — | 613.6K | 165.6K | 10.7K | 1.15M | 53.18% | ↗ |
| 121 | 2012 | Michael A. Jacobsen Vice President, Finance | 283.3K | — | 75.6K | 365.2K | 97.5K | 10.4K | 832.0K | 52.98% | ↗ |
| 122 | 2012 | Jayant Aphale, Ph.D. Senior Vice President, Technical Operations | 310.0K | — | — | 193.2K | 120.9K | 43.7K | 667.8K | 28.93% | ↗ |
| 123 | 2012 | Effie Toshav Former Senior Vice President and General Counsel | 66.4K | — | — | 38.9K | — | 108.0K | 213.3K | 18.23% | ↗ |
| 124 | 2012 | Arthur M. Krieg, M.D. Former Senior Vice President, Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 125 | 2011 | Christopher Garabedian President and Chief Executive Officer | 490.0K | 130.0K | — | 2.96M | 219.2K | 59.1K | 3.86M | 76.71% | ↗ |
| 126 | 2011 | Christopher Garabedian President and Chief Executive Officer | 490.0K | 30.0K | — | 2.96M | 219.2K | 59.1K | 3.86M | 76.71% | ↗ |
| 127 | 2011 | Effie Toshav Former Senior Vice President and General Counsel | 327.7K | — | — | 1.26M | — | 9.8K | 1.60M | 78.86% | ↗ |
| 128 | 2011 | Effie Toshav. Former Senior Vice President and General Counsel | 327.7K | — | — | 1.26M | — | 9.8K | 1.60M | 78.86% | ↗ |
| 129 | 2011 | Peter Linsley, Ph.D. Senior Vice President and Chief Scientific Officer | 242.7K | 175.0K | — | 949.4K | — | 52.5K | 1.42M | 66.88% | ↗ |
| 130 | 2011 | Edward M. Kaye, M.D. Senior Vice President and Chief Medical Officer | 194.6K | 130.0K | — | 791.0K | 60.9K | 9.2K | 1.19M | 66.71% | ↗ |
| 131 | 2011 | Edward M. Kaye, M.D. Senior Vice President, Chief Medical Officer | 194.6K | 130.0K | — | 791.0K | 60.9K | 9.2K | 1.19M | 66.71% | ↗ |
| 132 | 2011 | Edward M. Kaye, M.D. Senior Vice President, Chief Medical Officer | 194.6K | 130.0K | — | 791.0K | 60.9K | 9.2K | 1.19M | 66.71% | ↗ |
| 133 | 2011 | Michael A. Jacobsen Vice President, Finance | 88.8K | — | — | 209.3K | 20.0K | — | 318.2K | 65.80% | ↗ |
| 134 | 2010 | Graham Johnson, Ph.D. Senior Vice President of Preclinical Development and Research Leslie Hudson, Ph.D. Former President and Chief Executive Officer | 217.5K | — | — | 636.2K | — | 438.5K | 1.29M | 49.23% | ↗ |
| 135 | 2010 | J. David Boyle II Former Interim President and Chief Executive Officer and Current Senior Vice President and Chief Financial Officer | 358.4K | — | — | 328.1K | 88.7K | 9.8K | 785.0K | 41.79% | ↗ |
| 136 | 2010 | Graham Johnson, Ph.D. Senior Vice President of Preclinical Development and Research | 88.8K | 75.0K | — | 549.5K | 22.0K | 11.7K | 747.0K | 73.55% | ↗ |
| 137 | 2009 | Graham Johnson, Ph.D. Senior Vice President of Preclinical Development and Research Leslie Hudson, Ph.D. Former President and Chief Executive Officer | 480.0K | — | 114.4K | 273.0K | 181.4K | 94.1K | 1.14M | 33.89% | ↗ |
| 138 | 2009 | Graham Johnson, Ph.D. Senior Vice President of Preclinical Development and Research Leslie Hudson, Ph.D. Former President and Chief Executive Officer | 480.0K | 181.4K | 114.4K | 272.0K | — | 94.1K | 1.14M | 33.83% | ↗ |
| 139 | 2009 | Stephen B. Shrewsbury, M.D., | 264.3K | 59.3K | 81.6K | 514.7K | — | 55.6K | 975.4K | 61.13% | ↗ |
| 140 | 2009 | Paul Medeiros, | 165.2K | 150.0K | 110.0K | 371.8K | — | 11.6K | 808.7K | 59.58% | ↗ |
| 141 | 2009 | J. David Boyle II Former Interim President and Chief Executive Officer and Current Senior Vice President and Chief Financial Officer | 324.0K | — | 42.6K | 117.0K | 62.1K | 19.4K | 565.1K | 28.24% | ↗ |
| 142 | 2009 | J. David Boyle Former Interim President and Chief Executive Officer and Current Senior Vice President and Chief Financial Officer | 324.0K | 62.1K | 42.6K | 116.6K | — | 19.4K | 564.7K | 28.18% | ↗ |
| 143 | 2009 | Patrick L. Iversen, Ph.D., SVP of Research and Development | 265.0K | 42.1K | 29.0K | 77.7K | — | 9.8K | 423.7K | 25.19% | ↗ |
| 144 | 2008 | Graham Johnson, Ph.D. Senior Vice President of Preclinical Development and Research Leslie Hudson, Ph.D. Former President and Chief Executive Officer | 411.6K | — | 363.0K | 613.6K | 196.0K | 195.5K | 1.78M | 54.88% | ↗ |
| 145 | 2008 | Alan P. Timmins, Former President and Chief Operating Officer | 226.5K | — | — | — | — | 315.0K | 1.33M | 0.00% | ↗ |
| 146 | 2008 | Graham Johnson, Ph.D. Senior Vice President of Preclinical Development and Research Leslie Hudson, Ph.D. Former President and Chief Executive Officer | 411.6K | 196.0K | 109.0K | 137.5K | — | 195.8K | 1.05M | 23.48% | ↗ |
| 147 | 2008 | J. David Boyle II Former Interim President and Chief Executive Officer and Current Senior Vice President and Chief Financial Officer | 93.5K | — | — | 510.0K | 73.0K | 158.4K | 834.8K | 61.09% | ↗ |
| 148 | 2008 | Patrick L. Iversen, Ph.D., SVP of Research and Development | 265.0K | 49.7K | — | — | — | 9.2K | 626.3K | 0.00% | ↗ |
| 149 | 2008 | Dwight D. Weller, Senior Vice President of Chemistry and Manufacturing | 248.4K | 45.6K | — | — | — | 9.2K | 562.7K | 0.00% | ↗ |
| 150 | 2008 | Peter D. O'Hanley, Ph.D., M.D., SVP of Clinical Development and Regulatory Affairs | 269.5K | — | — | — | — | 9.2K | 538.0K | 0.00% | ↗ |
| 151 | 2008 | Mark M. Webber, Former Chief Financial Officer | 222.3K | — | — | — | — | — | 481.8K | 0.00% | ↗ |
| 152 | 2008 | J. David Boyle Former Interim President and Chief Executive Officer and Current Senior Vice President and Chief Financial Officer | 93.5K | 73.0K | — | 63.2K | — | 160.6K | 390.2K | 16.20% | ↗ |
| 153 | 2008 | K. Michael Forrest, Former Interim Chief Executive Officer | 117.0K | — | — | — | — | — | 117.0K | 0.00% | ↗ |
| 154 | 2007 | Alan P. Timmins, Former President and Chief Operating Officer | 310.0K | 43.5K | — | — | — | 9.0K | 918.8K | 0.00% | ↗ |
| 155 | 2007 | K. Michael Forrest, Former Interim Chief Executive Officer | 293.2K | — | — | — | — | 9.0K | 805.9K | 0.00% | ↗ |
| 156 | 2007 | Peter D. O'Hanley, Ph.D., M.D., SVP of Clinical Development and Regulatory Affairs | 260.0K | 42.0K | — | — | — | 9.0K | 616.2K | 0.00% | ↗ |
| 157 | 2007 | Patrick L. Iversen, Ph.D., SVP of Research and Development | 260.0K | 27.7K | — | — | — | 9.0K | 601.9K | 0.00% | ↗ |
| 158 | 2007 | Dwight D. Weller, Senior Vice President of Chemistry and Manufacturing | 240.0K | 30.0K | — | — | — | 9.0K | 554.7K | 0.00% | ↗ |
| 159 | 2007 | Mark M. Webber, Former Chief Financial Officer | 235.0K | 27.5K | — | — | — | 9.0K | 532.9K | 0.00% | ↗ |
| 160 | 2006 | Denis R. Burger, Ph.D. Chief Executive Officer | 375.0K | — | — | 807.8K | — | 8.8K | 1.19M | 67.79% | ↗ |
| 161 | 2006 | Alan P. Timmins, Former President and Chief Operating Officer | 300.0K | 110.0K | — | — | — | 8.0K | 1.05M | 0.00% | ↗ |
| 162 | 2006 | Alan P. Timmins, Former President and Chief Operating Officer | 300.0K | 110.0K | — | 632.3K | — | 8.8K | 1.05M | 60.16% | ↗ |
| 163 | 2006 | Patrick L. Iversen, Ph.D., SVP of Research and Development | 250.0K | 75.0K | — | 296.2K | — | 8.8K | 630.0K | 47.02% | ↗ |
| 164 | 2006 | Patrick L. Iversen, Ph.D., SVP of Research and Development | 250.0K | 75.0K | — | — | — | 8.8K | 630.0K | 0.00% | ↗ |
| 165 | 2006 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 230.0K | 50.0K | — | 290.5K | — | 8.8K | 579.3K | 50.15% | ↗ |
| 166 | 2006 | Dwight D. Weller, Senior Vice President of Chemistry and Manufacturing | 230.0K | 50.0K | — | — | — | 8.8K | 579.3K | 0.00% | ↗ |
| 167 | 2006 | Mark M. Webber, Former Chief Financial Officer | 225.0K | 50.0K | — | 280.1K | — | 8.8K | 563.9K | 49.67% | ↗ |
| 168 | 2006 | Mark M. Webber, Former Chief Financial Officer | 225.0K | 50.0K | — | — | — | 8.0K | 563.9K | 0.00% | ↗ |
| 169 | 2006 | Peter D. O'Hanley, Ph.D., M.D., SVP of Clinical Development and Regulatory Affairs | 250.0K | 50.0K | — | — | — | 8.8K | 546.0K | 0.00% | ↗ |
| 170 | 2006 | K. Michael Forrest, Former Interim Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 171 | 2005 | Denis R. Burger, Ph.D. Chief Executive Officer | 350.0K | 120.0K | — | 175.0K | — | 8.4K | 478.4K | 36.58% | ↗ |
| 172 | 2005 | Alan P. Timmins President and Chief Operating Officer | 300.0K | 100.0K | — | 175.0K | — | 8.4K | 408.4K | 42.85% | ↗ |
| 173 | 2005 | Patrick L. Iversen, Ph.D. Senior Vice President of Research and Development | 245.0K | 65.0K | — | 75.0K | — | 8.4K | 318.4K | 23.56% | ↗ |
| 174 | 2005 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 215.0K | 50.0K | — | 75.0K | — | 8.4K | 273.4K | 27.43% | ↗ |
| 175 | 2005 | Joseph B. Horn Vice President Cardiology | 266.9K | — | — | 100.0K | — | — | 266.9K | 37.47% | ↗ |
| 176 | 2004 | Denis R. Burger, Ph.D. Chief Executive Officer | 330.0K | 120.0K | — | — | — | 8.2K | 458.2K | 0.00% | ↗ |
| 177 | 2004 | Alan P. Timmins President and Chief Operating Officer | 295.0K | 90.0K | — | — | — | 8.2K | 393.2K | 0.00% | ↗ |
| 178 | 2004 | Patrick L. Iversen, Ph.D. Senior Vice President of Research and Development | 235.0K | 65.0K | — | — | — | 8.2K | 308.2K | 0.00% | ↗ |
| 179 | 2004 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 210.0K | 40.0K | — | — | — | 8.2K | 258.2K | 0.00% | ↗ |
| 180 | 2004 | Mark M. Webber Chief Financial Officer and Chief Information Officer | 200.0K | 50.0K | — | — | — | 7.6K | 257.6K | 0.00% | ↗ |
| 181 | 2004 | Joseph B. Horn Vice President Cardiology | — | — | — | — | — | — | — | — | ↗ |
| 182 | 2003 | Denis R. Burger, Ph.D Chief Executive Officer | 315.0K | 105.0K | — | — | — | 8.0K | 428.0K | 0.00% | ↗ |
| 183 | 2003 | Denis R. Burger, Ph.D. Chief Executive Officer | 315.0K | 105.0K | — | — | — | 8.0K | 428.0K | 0.00% | ↗ |
| 184 | 2003 | Alan P. Timmins President and Chief Operating Officer | 275.0K | 70.0K | — | 25.0K | — | 8.0K | 353.0K | 7.08% | ↗ |
| 185 | 2003 | Alan P. Timmins President and Chief Operating Officer | 275.0K | 70.0K | — | 25.0K | — | 8.0K | 353.0K | 7.08% | ↗ |
| 186 | 2003 | Patrick L. Iversen, Ph.D. Senior Vice President of Research and Development | 225.0K | 60.0K | — | — | — | 8.0K | 293.0K | 0.00% | ↗ |
| 187 | 2003 | Patrick L. Iversen, Ph.D. Senior Vice President of Research and Development | 225.0K | 60.0K | — | — | — | 8.0K | 293.0K | 0.00% | ↗ |
| 188 | 2003 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 205.0K | 40.0K | — | — | — | 8.0K | 253.0K | 0.00% | ↗ |
| 189 | 2003 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 205.0K | 40.0K | — | — | — | 8.0K | 253.0K | 0.00% | ↗ |
| 190 | 2003 | Mark M. Webber Chief Financial Officer and Chief Information Officer | 190.0K | 50.0K | — | — | — | 7.2K | 247.2K | 0.00% | ↗ |
| 191 | 2003 | Mark M. Webber Chief Financial Officer and Chief Information Officer | 190.0K | 50.0K | — | — | — | 7.2K | 247.2K | 0.00% | ↗ |
| 192 | 2002 | Denis R. Burger, Ph.D. Chief Executive Officer | 300.0K | 100.0K | — | — | — | 6.8K | 406.8K | 0.00% | ↗ |
| 193 | 2002 | Denis R. Burger, Ph.D Chief Executive Officer | 300.0K | 100.0K | — | 330.0K | — | 6.8K | 406.8K | 81.11% | ↗ |
| 194 | 2002 | Alan P. Timmins President and Chief Operating Officer | 260.0K | 95.0K | — | 148.5K | — | 6.8K | 361.8K | 41.04% | ↗ |
| 195 | 2002 | Alan P. Timmins President and Chief Operating Officer | 260.0K | 95.0K | — | — | — | 6.8K | 361.8K | 0.00% | ↗ |
| 196 | 2002 | David H. Mason, Jr., M.D. Senior Vice President of Clinical Development and Regulatory Affairs | 235.1K | 50.0K | — | 92.4K | — | 6.8K | 291.9K | 31.65% | ↗ |
| 197 | 2002 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 200.5K | 50.0K | — | 92.4K | — | 6.8K | 257.3K | 35.92% | ↗ |
| 198 | 2002 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 200.5K | 50.0K | — | 92.4K | — | 6.8K | 257.3K | 35.92% | ↗ |
| 199 | 2002 | Patrick L. Iversen, Ph.D. Senior Vice President of Research and Development | 210.0K | 40.0K | — | 92.4K | — | 6.8K | 256.8K | 35.98% | ↗ |
| 200 | 2002 | Patrick L. Iversen, Ph.D. Senior Vice President of Research and Development | 210.0K | 40.0K | — | 92.4K | — | 6.8K | 256.8K | 35.98% | ↗ |
| 201 | 2002 | Mark M. Webber Chief Financial Officer and Chief Information Officer | 180.0K | 30.0K | — | 82.5K | — | 6.6K | 216.6K | 38.09% | ↗ |
| 202 | 2002 | Mark M. Webber Chief Financial Officer and Chief Information Officer | 180.0K | 30.0K | — | 82.5K | — | 6.6K | 216.6K | 38.09% | ↗ |
| 203 | 2001 | Denis R. Burger, Ph.D Chief Executive Officer | 280.4K | 100.0K | — | — | — | 6.8K | 387.2K | 0.00% | ↗ |
| 204 | 2001 | Alan P. Timmins President and Chief Operating Officer | 230.4K | 75.0K | — | — | — | 6.8K | 312.2K | 0.00% | ↗ |
| 205 | 2001 | David H. Mason, Jr., M.D. Senior Vice President of Clinical Development and Regulatory Affairs | 225.4K | — | — | — | — | 6.8K | 232.2K | 0.00% | ↗ |
| 206 | 2001 | Patrick L. Iversen, Ph.D. Senior Vice President of Research and Development | 200.4K | — | — | — | — | 6.8K | 207.2K | 0.00% | ↗ |
| 207 | 2001 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 190.4K | — | — | — | — | 6.8K | 197.2K | 0.00% | ↗ |
| 208 | 2001 | Mark M. Webber Chief Financial Officer and Chief Information Officer | 165.4K | 15.0K | — | — | — | 4.6K | 185.0K | 0.00% | ↗ |
| 209 | 2000 | Denis R. Burger, Ph.D Chief Executive Officer | 265.4K | — | — | 200.0K | — | 6.8K | 272.2K | 73.48% | ↗ |
| 210 | 2000 | Alan P. Timmins President and Chief Operating Officer | 200.4K | — | — | 135.0K | — | 6.8K | 207.2K | 65.15% | ↗ |
| 211 | 2000 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 175.4K | 25.0K | — | 84.0K | — | 6.8K | 207.2K | 40.54% | ↗ |
| 212 | 2000 | Patrick L. Iversen, Ph.D. Senior Vice President of Research and Development | 175.4K | 25.0K | — | 84.0K | — | 4.8K | 205.2K | 40.94% | ↗ |
| 213 | 2000 | Mark M. Webber Chief Financial Officer and Chief Information Officer | 120.4K | — | — | 132.0K | — | 4.6K | 125.0K | 105.62% | ↗ |
| 214 | 2000 | David H. Mason, Jr., M.D. Senior Vice President of Clinical Development and Regulatory Affairs | 37.8K | — | — | 184.0K | — | — | 37.8K | 487.40% | ↗ |
| 215 | 1999 | Denis R. Burger, Ph.D Chief Executive Officer | 250.4K | — | — | — | — | 7.5K | 257.9K | 0.00% | ↗ |
| 216 | 1999 | Alan P. Timmins President and Chief Operating Officer | 185.4K | — | — | — | — | 5.5K | 190.9K | 0.00% | ↗ |
| 217 | 1999 | Patrick L. Iversen, Ph.D. Senior Vice President of Research and Development | 160.4K | — | — | 28.0K | — | 4.8K | 165.2K | 16.95% | ↗ |
| 218 | 1999 | Dwight D. Weller, Ph.D. Senior Vice President of Chemistry and Manufacturing | 160.4K | — | — | — | — | 4.8K | 165.2K | 0.00% | ↗ |
| 219 | 1999 | David H. Mason, Jr., M.D. Senior Vice President of Clinical Development and Regulatory Affairs | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Douglas S. Ingram | Chief Executive Officer & Director | 2M | male |
| Louise R. Rodino-Klapac | President of Research & Development and Technical Operations | 1M | — |
| Ian Michael Estepan | President & Chief Operating Officer | 1M | male |
| Cristin L. Rothfuss | Executive Vice President, General Counsel & Company Secretary | 806.8K | female |
| Ryan H. Wong | Executive Vice President & Chief Financial Officer | 633.9K | male |
| Joseph Bratica | Controller & Vice President | 438.5K | male |
| Alison Nasisi | Executive Vice President & Chief People Officer | — | female |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations | — | — |
| Diane L. Berry | Executive Vice President and Chief of Global Policy & Advocacy Officer | — | — |
| James Richardson | Executive VP & Chief Medical Officer | — | — |
| Mary Jenkins | Senior Manager of Investor Relations | — | — |
| Patrick Moss | Executive Vice President & Chief Commercial Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-07-14 | 2023-08-21 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-06-13 | 2023-07-11 | Josh Gottheimer | NJ05 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-04-10 | 2023-05-19 | Daniel Goldman | NY10 | — | Sale | $15,001 - $50,000 | ↗ |
| 2023-03-06 | 2023-04-20 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-03-06 | 2023-04-17 | Daniel Goldman | NY10 | — | Purchase | $15,001 - $50,000 | ↗ |
| 2023-01-31 | 2023-02-24 | Daniel Goldman | NY10 | — | Sale | $1,001 - $15,000 | ↗ |
| 2020-11-06 | 2020-12-09 | Josh Gottheimer | NJ05 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-09-14 | 2020-10-14 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2020-06-10 | 2020-07-17 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2019-12-13 | 2020-01-06 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SRPT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
